BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017;111:176-81. [DOI: 10.1016/j.lungcan.2017.07.024] [Cited by in Crossref: 355] [Cited by in F6Publishing: 426] [Article Influence: 59.2] [Reference Citation Analysis]
Number Citing Articles
1 Cui H, Zeng L, Li R, Li Q, Hong C, Zhu H, Chen L, Liu L, Zou X, Xiao L. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. Clin Radiol 2023;78:e37-44. [PMID: 36257868 DOI: 10.1016/j.crad.2022.09.113] [Reference Citation Analysis]
2 Hu X, Tian T, Zhang X, Sun Q, Chen Y, Jiang W. Neutrophil-to-lymphocyte and hypopharyngeal cancer prognosis: System review and meta-analysis. Head Neck 2023;45:492-502. [PMID: 36367335 DOI: 10.1002/hed.27246] [Reference Citation Analysis]
3 Wang J, Jiang P, Huang Y, Tu Y, Zhou Q, Li N, Kong W, Yuan R. Prognostic Value of the Cutoffs for HALP in Endometrial Cancer. Am J Clin Oncol 2023. [PMID: 36700534 DOI: 10.1097/COC.0000000000000977] [Reference Citation Analysis]
4 Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, Xiao C, Zhang Y, Su Y, Li G, Wu F. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1011810] [Reference Citation Analysis]
5 Jeleń A, Żebrowska-nawrocka M, Sałagacka-kubiak A, Zawadzka I, Łochowski M, Balcerczak E. The Interaction between Four Polymorphisms and Haplotype of ABCB1, the Risk of Non-Small Cell Lung Cancer, and the Disease Phenotype. Journal of Oncology 2023;2023:1-8. [DOI: 10.1155/2023/7925378] [Reference Citation Analysis]
6 Chan A, Bentzen S, Rout A, Miller K. Predicting if Lung Cancer Will Relapse-The Role of Neutrophil/Lymphocyte Ratio. Hematol Oncol Stem Cell Ther 2023;16:158-61. [PMID: 34562406 DOI: 10.1016/j.hemonc.2021.08.003] [Reference Citation Analysis]
7 Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol 2022;12:1091088. [PMID: 36727075 DOI: 10.3389/fonc.2022.1091088] [Reference Citation Analysis]
8 Levantini E. Editorial: Impact of tumor microenvironment on lung cancer. Front Oncol 2023;13:1136803. [PMID: 36712496 DOI: 10.3389/fonc.2023.1136803] [Reference Citation Analysis]
9 Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study. Thorac Cancer 2023. [PMID: 36635979 DOI: 10.1111/1759-7714.14798] [Reference Citation Analysis]
10 Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, Nakayama H, Kubo Y, Ito K, Nakamura S, Takahashi K, Inaba K, Murakami N, Saito T, Okamoto H, Itami J, Kusumoto M, Ohe Y, Igaki H. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 2023;180:109454. [PMID: 36640944 DOI: 10.1016/j.radonc.2022.109454] [Reference Citation Analysis]
11 Bamias A, Merseburger A, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. J Immunother Cancer 2023;11. [PMID: 36627145 DOI: 10.1136/jitc-2022-005977] [Reference Citation Analysis]
12 Ren Z, Yang J, Liang J, Xu Y, Lu G, Han Y, Zhu J, Tan H, Xu T, Ren M. Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic value for recurrent and metastatic breast cancer. Front Surg 2022;9:927491. [PMID: 36684341 DOI: 10.3389/fsurg.2022.927491] [Reference Citation Analysis]
13 Li T, Liu T, Zhao L, Liu L, Zheng X, Wang J, Zhang F, Hu Y. Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study. Front Oncol 2022;12:976078. [PMID: 36686795 DOI: 10.3389/fonc.2022.976078] [Reference Citation Analysis]
14 Ge MY, Liu ZP, Pan Y, Wang JY, Wang X, Dai HS, Gao SY, Zhong SY, Che XY, Zuo JH, Liu YH, Liu XC, Fan HN, Chen WY, Wang ZR, Yin XY, Bai J, Zhang YQ, Jiang Y, Gong Y, Chen ZY. Assessment of the prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in perihilar cholangiocarcinoma patients following curative resection: A multicenter study of 333 patients. Front Oncol 2022;12:1104810. [PMID: 36686802 DOI: 10.3389/fonc.2022.1104810] [Reference Citation Analysis]
15 Matsunaga T, Saito H, Fukumoto Y, Kuroda H, Taniguchi K, Takahashi S, Osaki T, Iwamoto A, Fukuda K, Shimizu S, Shishido Y, Miyatani K, Fujiwara Y. The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment. Surg Today 2023. [PMID: 36595075 DOI: 10.1007/s00595-022-02638-w] [Reference Citation Analysis]
16 Rönnau ADRO, Berto MD, Bica CG, Alves RV, Rotta LN. Platelet Concentration and Platelet/Lymphocyte Ratio as Prognostic Indicators in Luminal Breast Cancer. JMP 2023;4:15-27. [DOI: 10.3390/jmp4010002] [Reference Citation Analysis]
17 Ali WAS, Huang X, Wu Y, Ma Y, Pan H, Liao J, Yang Z, Hong S, Yang Y, Huang Y, Zhao Y, Fang W, Zhao H, Zhang L. Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma. Cancer Control 2023;30:10732748221148912. [PMID: 36592162 DOI: 10.1177/10732748221148912] [Reference Citation Analysis]
18 Tanaka T, Yoshida T, Masuda K, Takeyasu Y, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respir Investig 2023;61:74-81. [PMID: 36460585 DOI: 10.1016/j.resinv.2022.10.003] [Reference Citation Analysis]
19 Diker O, Olgun P, Balyemez U, Sigit Ikiz S. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. Cureus 2023;15:e33234. [PMID: 36733552 DOI: 10.7759/cureus.33234] [Reference Citation Analysis]
20 Su N, Zheng Y, Zhang X, Tang X, Tang LW, Wang Q, Chen X, Wang X, Wen Y, Feng X, Zhou Q, Zhou J, Li Y, Shang S. Platelet-to-lymphocyte ratio and the first occurrence of peritonitis in peritoneal dialysis patients. BMC Nephrol 2022;23:415. [PMID: 36585653 DOI: 10.1186/s12882-022-03038-5] [Reference Citation Analysis]
21 Qi T, Cao Y. Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non‐small cell lung cancer. CPT Pharmacom & Syst Pharma 2022. [DOI: 10.1002/psp4.12896] [Reference Citation Analysis]
22 Yang J, Wan Y, Ni Q, Zuo J, Wang J, Zhang X, Zhou L. Quantifying causal effects from observed data using quasi-intervention. BMC Med Inform Decis Mak 2022;22:337. [PMID: 36544217 DOI: 10.1186/s12911-022-02086-z] [Reference Citation Analysis]
23 Yang C, Hu BW, Tang F, Zhang Q, Quan W, Wang J, Wang ZF, Li YR, Li ZQ. Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis. J Clin Med 2022;11. [PMID: 36556130 DOI: 10.3390/jcm11247514] [Reference Citation Analysis]
24 El-dawa A, Elsaid A, refaat S, El-khawaga O. Association of A1AT genetic polymorphism and NSCLC: a case- control study in Egyptian population.. [DOI: 10.21203/rs.3.rs-2366803/v1] [Reference Citation Analysis]
25 Chelariu AC, Coman AE, Lionte C, Gorciac V, Sorodoc V, Haliga RE, Petris OR, Bologa C, Puha G, Stoica A, Constantin M, Sirbu O, Ceasovschih A, Sorodoc L. The Value of Early and Follow-Up Elevated Scores Based on Peripheral Complete Blood Cell Count for Predicting Adverse Outcomes in COVID-19 Patients. J Pers Med 2022;12. [PMID: 36556258 DOI: 10.3390/jpm12122037] [Reference Citation Analysis]
26 Zhang J, Jiang S, Li S, Jiang J, Mei J, Chen Y, Ma Y, Liu Y, Liu Y. Nanotechnology: A New Strategy for Lung Cancer Treatment Targeting Pro-Tumor Neutrophils. Engineering 2022. [DOI: 10.1016/j.eng.2022.11.006] [Reference Citation Analysis]
27 Wu W, Chen X, Li N, Luo Q, Zou L. A neutrophil/lymphocyte Ratio as a Significant Predictor for Patients with low-risk and early-stage Extranodal NK-T-cell Lymphoma. Indian J Hematol Blood Transfus 2022. [DOI: 10.1007/s12288-022-01578-2] [Reference Citation Analysis]
28 Feng W, Liu Y, Zhu L, Xu L, Shen H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study. BMC Gastroenterol 2022;22:485. [PMID: 36424535 DOI: 10.1186/s12876-022-02571-9] [Reference Citation Analysis]
29 Chen F, Chao M, Huang T, Guo S, Zhai Y, Wang Y, Wang N, Xie X, Wang L, Ji P. The role of preoperative inflammatory markers in patients with central nervous system tumors, focus on glioma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1055783] [Reference Citation Analysis]
30 Liang W, Xu X, Liu Y, Cui J, Gao Y, Wang C, Zhuang Z, Zhang K, Xi H, Cai A, Wei B, Chen L. Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis. World J Surg Onc 2022;20:356. [DOI: 10.1186/s12957-022-02822-9] [Reference Citation Analysis]
31 Nindra U, Shahnam A, Stevens S, Pal A, Nagrial A, Lee J, Yip PY, Adam T, Boyer M, Kao S, Bray V. Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab. Thorac Cancer 2022;13:3058-62. [PMID: 36111516 DOI: 10.1111/1759-7714.14646] [Reference Citation Analysis]
32 Huang Y, Zhao JJ, Soon YY, Wong A, Aminkeng F, Ang Y, Asokumaran Y, Low JL, Lee M, Choo JRE, Chan G, Kee A, Tay SH, Goh BC, Soo RA. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Thorac Cancer 2022;13:3152-61. [PMID: 36177913 DOI: 10.1111/1759-7714.14667] [Reference Citation Analysis]
33 Wan M, Ding Y, Mao C, Ma X, Li N, Xiao C, Qian J, Jiang H, Zheng Y, Wu L, Teng L, Xu N. Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1029960] [Reference Citation Analysis]
34 Berz AM, Dromain C, Vietti-violi N, Boughdad S, Duran R. Tumor response assessment on imaging following immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.982983] [Reference Citation Analysis]
35 Li L, Shen Q, Rao S. Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic kidney disease in patients with type 2 diabetes.. [DOI: 10.21203/rs.3.rs-2180928/v1] [Reference Citation Analysis]
36 Liu S, Zhao L, Zhou G. Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. Front Genet 2022;13:1016085. [DOI: 10.3389/fgene.2022.1016085] [Reference Citation Analysis]
37 Brkic FF, Stoiber S, Al-gboore S, Quint C, Schnoell J, Scheiflinger A, Heiduschka G, Brunner M, Kadletz-wanke L. Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma. Nutrients 2022;14:4337. [DOI: 10.3390/nu14204337] [Reference Citation Analysis]
38 Turri G, Caligola S, Ugel S, Conti C, Zenuni S, Barresi V, Ruzzenente A, Lippi G, Scarpa A, Guglielmi A, Pedrazzani C. Analysis of pre-diagnostic values of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer.. [DOI: 10.21203/rs.3.rs-2146681/v1] [Reference Citation Analysis]
39 Zhang L, Xu C, Zhang X, Wang J, Jiang H, Chen J, Zhang H. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [18F]FDG PET/CT metabolic parameters, inflammatory markers, and clinical variables. Eur Radiol 2022. [PMID: 36222865 DOI: 10.1007/s00330-022-09150-2] [Reference Citation Analysis]
40 Kast RE. High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth-Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen. Cancers (Basel) 2022;14:4965. [PMID: 36230888 DOI: 10.3390/cancers14194965] [Reference Citation Analysis]
41 Yang Z, Zhang D, Zeng H, Fu Y, Hu Z, Pan Y, Chen J, Wang J, Zhang Y, Zhou Z, Xu L, Hu D, Chen M. Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma. J Inflamm Res 2022;15:5721-31. [PMID: 36238770 DOI: 10.2147/JIR.S385921] [Reference Citation Analysis]
42 Picarelli H, Yamaki VN, Solla DJF, Neville IS, Santos AGD, Freitas BSAG, Diep C, Paiva WS, Teixeira MJ, Figueiredo EG. The preoperative neutrophil-to-lymphocyte ratio predictive value for survival in patients with brain metastasis. Arq Neuropsiquiatr 2022;80:922-8. [PMID: 36261127 DOI: 10.1055/s-0042-1755324] [Reference Citation Analysis]
43 Chen W, Li D, Bian X, Wu Y, Xu M, Wu M, Tao M. Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy. Nutr Cancer 2023;75:207-18. [PMID: 36190755 DOI: 10.1080/01635581.2022.2123533] [Reference Citation Analysis]
44 Wang F, Yang M, Luo W, Zhou Q. Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.10.002] [Reference Citation Analysis]
45 Dong FC, Tan WT, Wang XB, Zheng X, Huang Y, Li BL, Meng ZJ, Gao YH, Qian ZP, Liu F, Lu XB, Shang J, Shi Y, Zheng YB, Yan HD, Zhang Y, Xu BY, Hou YX, Zhang Q, Xiong Y, Zou CC, Chen J, Huang ZB, Jiang XH, Luo S, Chen YY, Gao N, Liu CY, Yuan W, Mei X, Li J, Li T, Zheng RJ, Zhou XY, Chen JJ, Deng GH, Mei XX, Zhang WT, Li H. The neutrophil-to-lymphocyte ratio represents a systemic inflammation marker and reflects the relationship with 90-day mortality in non-cirrhotic chronic severe hepatitis. J Dig Dis 2022;23:587-96. [PMID: 36326787 DOI: 10.1111/1751-2980.13143] [Reference Citation Analysis]
46 Wen X, Leng P, Wang J, Yang G, Zu R, Jia X, Zhang K, Mengesha BA, Huang J, Wang D, Luo H. Clinlabomics: leveraging clinical laboratory data by data mining strategies. BMC Bioinformatics 2022;23. [DOI: 10.1186/s12859-022-04926-1] [Reference Citation Analysis]
47 Zheng C, Zhang G, Xie K, Diao Y, Luo C, Wang Y, Shen Y, Xue Q. Pan-Cancer Analysis and Experimental Validation Identify ACOT7 as a Novel Oncogene and Potential Therapeutic Target in Lung Adenocarcinoma. Cancers (Basel) 2022;14:4522. [PMID: 36139682 DOI: 10.3390/cancers14184522] [Reference Citation Analysis]
48 Gründing AR, Schneider MA, Richtmann S, Kriegsmann M, Winter H, Martinez-delgado B, Varona S, Liu B, Deluca DS, Held J, Wrenger S, Muley T, Meister M, Welte T, Janciauskiene S. Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and SREBF1 Gene. Cancers 2022;14:4454. [DOI: 10.3390/cancers14184454] [Reference Citation Analysis]
49 Bir Yucel K, Karabork Kilic AC, Sutcuoglu O, Yazıcı O, Aydos U, Kilic K, Özdemir N. Effects of Sarcopenia, Myosteatosis, and the Prognostic Nutritional Index on Survival in Stage 2 and 3 Gastric Cancer Patients. Nutr Cancer 2023;75:368-75. [PMID: 36093734 DOI: 10.1080/01635581.2022.2121845] [Reference Citation Analysis]
50 Song M, Zhang Q, Song C, Liu T, Zhang X, Ruan G, Tang M, Zhang X, Xie H, Zhang H, Ge Y, Li X, Zhang K, Yang M, Li Q, Liu X, Lin S, Xu Y, Li B, Li X, Wang K, Xu H, Li W, Shi H. Handgrip weakness, systemic inflammation indicators, and overall survival in lung cancer patients with well performance status: A large multicenter observational study. Cancer Med 2022. [PMID: 36073671 DOI: 10.1002/cam4.5180] [Reference Citation Analysis]
51 De Giglio A, Aprile M, Di Federico A, Sperandi F, Melotti B, Gelsomino F, Ardizzoni A. Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). IJMS 2022;23:10292. [DOI: 10.3390/ijms231810292] [Reference Citation Analysis]
52 Varady NH, Schwab PE, Kheir MM, Dilley JE, Bedair H, Chen AF. Synovial Fluid and Serum Neutrophil-to-Lymphocyte Ratio: Novel Biomarkers for the Diagnosis and Prognosis of Native Septic Arthritis in Adults. J Bone Joint Surg Am 2022;104:1516-22. [PMID: 35726876 DOI: 10.2106/JBJS.21.01279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Zhou J, Wong AH, Wang H, Jin S, Tan F, Chen Y, He S, Shen G, Frey B, Fietkau R, Hecht M, Carr SR, Wang R, Shen B, Schrump DS, Ma H, Gaipl US. Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials. Front Immunol 2022;13:961926. [DOI: 10.3389/fimmu.2022.961926] [Reference Citation Analysis]
54 Han R, Tian Z, Jiang Y, Guan G, Wang X, Sun X, Yu Y, Jing X. Prognostic significance of the systemic immune inflammation index in patients with metastatic and unresectable pancreatic cancer. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.915599] [Reference Citation Analysis]
55 Zhou K, Cao J, Lin H, Liang L, Shen Z, Wang L, Peng Z, Mei J. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. Front Oncol 2022;12:962173. [DOI: 10.3389/fonc.2022.962173] [Reference Citation Analysis]
56 Liu T, Li W, Zhang Z, Jiang T, Fei Y, Huang J, Xie Q. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis. BMC Pulm Med 2022;22:316. [PMID: 35978395 DOI: 10.1186/s12890-022-02106-8] [Reference Citation Analysis]
57 Huang R, Zheng Y, Zou W, Liu C, Liu J, Yue J, Meng L. Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/3781109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Arasanz H, Bocanegra AI, Morilla I, Fernández-irigoyen J, Martínez-aguillo M, Teijeira L, Garnica M, Blanco E, Chocarro L, Ausin K, Zuazo M, Fernández-hinojal G, Echaide M, Fernández-rubio L, Piñeiro-hermida S, Ramos P, Mezquita L, Escors D, Vera R, Kochan G. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. Cancers 2022;14:3846. [DOI: 10.3390/cancers14163846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Platini H, Ferdinand E, Kohar K, Prayogo SA, Amirah S, Komariah M, Maulana S. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina 2022;58:1069. [DOI: 10.3390/medicina58081069] [Reference Citation Analysis]
60 Jia J, Zeng X, Li C, Yang L, Huang Y, Tong X, Jiang Q, Zhang P, Tao K. A Combination of Preoperative Computed Tomography-Defined Sarcopenia and Systemic Inflammation on Survival in Patients with Poorly Differentiated Neuroendocrine Neoplasms Following Radical Resection. Nutr Cancer 2023;75:186-96. [PMID: 35920394 DOI: 10.1080/01635581.2022.2102660] [Reference Citation Analysis]
61 Chong H, Li J, Chen C, Wang W, Liao D, Zhang K. The diagnostic model for early detection of gestational diabetes mellitus and gestational diabetic nephropathy. J Clin Lab Anal 2022;:e24627. [PMID: 35917438 DOI: 10.1002/jcla.24627] [Reference Citation Analysis]
62 Zhang Z, Xie T, Qi C, Zhang X, Shen L, Peng Z. Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors. Cancers 2022;14:3736. [DOI: 10.3390/cancers14153736] [Reference Citation Analysis]
63 Fang Y, Su C. Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases. Front Oncol 2022;12:893716. [DOI: 10.3389/fonc.2022.893716] [Reference Citation Analysis]
64 Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol 2022;20:242. [PMID: 35897018 DOI: 10.1186/s12957-022-02695-y] [Reference Citation Analysis]
65 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
66 Mouillot P, Witko-Sarsat V, Wislez M. [Neutrophil plasticity: A new key in the understanding of onco-immunology]. Rev Mal Respir 2022:S0761-8425(22)00257-1. [PMID: 35871052 DOI: 10.1016/j.rmr.2022.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Zhang Q, Gong X, Sun L, Miao L, Zhou Y. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. Front Oncol 2022;12:791496. [DOI: 10.3389/fonc.2022.791496] [Reference Citation Analysis]
68 Kong Y, Zhao X, Xu M, Pan J, Ma Y, Zou L, Peng Q, Zhang J, Su C, Xu Z, Zhou W, Peng Y, Yang J, Zhou C, Li Y, Guo Q, Chen G, Wu H, Xing P, Zhang L. PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study. Front Immunol 2022;13:952066. [DOI: 10.3389/fimmu.2022.952066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhao T. Prognostic assessment of C‑reactive protein and neutrophil to lymphocyte ratio in patients with non-small cell lung cancer. Wien Klin Wochenschr 2022. [PMID: 35794490 DOI: 10.1007/s00508-022-02049-4] [Reference Citation Analysis]
70 Park Y, Chang AR. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy. Korean J Gastroenterol 2022;79:252-259. [DOI: 10.4166/kjg.2022.021] [Reference Citation Analysis]
71 Yang M, Zhang Q, Ge Y, Tang M, Hu C, Wang Z, Zhang X, Song M, Ruan G, Zhang X, Liu T, Xie H, Zhang H, Zhang K, Li Q, Li X, Liu X, Lin S, Shi H. Prognostic Roles of Inflammation- and Nutrition-Based Indicators for Female Patients with Cancer. J Inflamm Res 2022;15:3573-86. [PMID: 35747251 DOI: 10.2147/JIR.S361300] [Reference Citation Analysis]
72 Cortellini A, Ricciuti B, Borghaei H, Naqash AR, D'Alessio A, Fulgenzi CAM, Addeo A, Banna GL, Pinato DJ. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022. [PMID: 35727053 DOI: 10.1002/cncr.34348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
73 Sakane T, Okuda K, Matsui T, Oda R, Tatematsu T, Yokota K, Nakanishi R. Prognostic value of systemic inflammatory markers and the nutrition status in thymic epithelial tumors with complete resection. Thorac Cancer 2022. [PMID: 35715991 DOI: 10.1111/1759-7714.14485] [Reference Citation Analysis]
74 Li Y, Xin G, Li S, Dong Y, Zhu Y, Yu X, Wan C, Li F, Wei Z, Wang Y, Zhang K, Chen Q, Niu H, Huang W. PD-L1 Regulates Platelet Activation and Thrombosis via Caspase-3/GSDME Pathway. Front Pharmacol 2022;13:921414. [DOI: 10.3389/fphar.2022.921414] [Reference Citation Analysis]
75 Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax 2022:thoraxjnl-2020-215614. [PMID: 35688624 DOI: 10.1136/thoraxjnl-2020-215614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wu M, Ye P, Zhang W, Zhu H, Yu H. Prognostic role of an inflammation scoring system in radical resection of oral squamous cell carcinoma. BMC Oral Health 2022;22:226. [PMID: 35676658 DOI: 10.1186/s12903-022-02261-8] [Reference Citation Analysis]
77 Shindo T, Maehana T, Tanaka T, Hashimoto K, Kobayashi K, Takahashi A, Hotta H, Kunishima Y, Taguchi K, Tachiki H, Ito N, Matsukawa M, Kato R, Miyamoto S, Hinotsu S, Masumori N. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study. Int J Urol 2022. [PMID: 35654444 DOI: 10.1111/iju.14941] [Reference Citation Analysis]
78 Aizawa R, Nakamura Y, Ikeda T, Aibara N, Kutsuna YJ, Kurosaki T, Aki K, Junya H, Nakagawa H, Sato K, Kodama Y, Nakashima MN, Nakashima M, Mukae H, Ohyama K. Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy. Clinica Chimica Acta 2022. [DOI: 10.1016/j.cca.2022.05.021] [Reference Citation Analysis]
79 Qin A, Lima F, Bell S, Kalemkerian GP, Schneider BJ, Ramnath N, Lew M, Krishnan S, Mohammed S, Rao A, Frankel TL. Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. Sci Rep 2022;12:9054. [PMID: 35641540 DOI: 10.1038/s41598-022-13236-8] [Reference Citation Analysis]
80 Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, Yoshiike F, Hama M, Nishie K, Kondo D, Agatsuma T, Kato A, Takata M, Kanda S, Hanaoka M, Koizumi T. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy. Thorac Cancer 2022. [PMID: 35616056 DOI: 10.1111/1759-7714.14484] [Reference Citation Analysis]
81 Feng C, Yu H, Lei H, Cao H, Chen M, Liu S. A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer. BMC Palliat Care 2022;21:81. [PMID: 35585628 DOI: 10.1186/s12904-022-00972-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Xu ZY, Yao XC, Shi XJ, Du XR. Significance of preoperative peripheral blood neutrophil-lymphocyte ratio in predicting postoperative survival in patients with multiple myeloma bone disease. World J Clin Cases 2022; 10(14): 4380-4394 [DOI: 10.12998/wjcc.v10.i14.4380] [Reference Citation Analysis]
83 Wang H, Li C, Yang R, Jin J, Liu D, Li W. Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis. PLoS One 2022;17:e0268288. [PMID: 35522679 DOI: 10.1371/journal.pone.0268288] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Xu J, Li S, Feng Y, Zhang J, Peng Y, Wang X, Wang H. The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery. CMAR 2022;Volume 14:1795-806. [DOI: 10.2147/cmar.s361462] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Arasanz H, Bocanegra A, Morilla I, Fernández-irigoyen J, Martínez-aguillo M, Teijeira L, Garnica M, Blanco E, Chocarro L, Ausin K, Zuazo M, Fernández-hinojal G, Echaide M, Fernández-rubio L, Piñeiro-hermida S, Ramos P, Mezquita L, Escors D, Vera R, Kochan G. Circulating Low Density Neutrophils Are Associated with Resistance to First-Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer.. [DOI: 10.1101/2022.04.27.22273598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Fang Y, Li X, Jiang Y, Ge Z, Wang F. Blocking TGF-β Expression Attenuates Tumor Growth in Lung Cancers, Potentially Mediated by Skewing Development of Neutrophils. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/3447185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Yang S, Huang Y, Zhao Q. Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer. Front Immunol 2022;13:878740. [DOI: 10.3389/fimmu.2022.878740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
88 Osunronbi T, Borbas B, Lusta H, Sofela A, Sharma H. Preoperative lymphocyte percentage and neutrophil-lymphocyte ratio are useful predictors of 30-day postoperative complications after lumbar fusion. Surgical Neurology International 2022;13:145. [DOI: 10.25259/sni_160_2022] [Reference Citation Analysis]
89 Nishioka N, Naito T, Miyawaki T, Yabe M, Doshita K, Kodama H, Miyawaki E, Iida Y, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer. Thorac Cancer 2022. [PMID: 35420262 DOI: 10.1111/1759-7714.14421] [Reference Citation Analysis]
90 Han S, Qu F, Wang P, Liu Y, Li S, Yan C. Development and Validation of a Nomogram Model Based on Hematological Indicators for Predicting the Prognosis of Diffused Gliomas. Front Surg 2022;9:803237. [DOI: 10.3389/fsurg.2022.803237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Yao Y, Tang D, Gao W, Zhang H. Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC? Front Surg 2022;9:843987. [DOI: 10.3389/fsurg.2022.843987] [Reference Citation Analysis]
92 Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Valente M, Sciacovelli AM, Chiarion Sileni V, Ascierto PA, Stigliano L, Strippoli S. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. J Transl Med 2022;20:159. [PMID: 35382857 DOI: 10.1186/s12967-022-03359-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Tankel J, Calderone A, Garcia-Luna JLR, Mueller CL, Najmeh S, Spicer J, Mulder D, Ferri L, Cools-Lartigue J. Changes in Perioperative Platelet Lymphocyte Ratio Predict Survival in Oesophago-Gastric Adenocarcinoma. Ann Surg Oncol 2022. [PMID: 35377063 DOI: 10.1245/s10434-022-11475-7] [Reference Citation Analysis]
94 Wei S, Shao J, Wang J, Wang G. The preoperative hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for non-small cell lung cancer patients undergoing adjuvant chemotherapy: a retrospective study. Ann Transl Med 2022;10:457. [PMID: 35571436 DOI: 10.21037/atm-22-1097] [Reference Citation Analysis]
95 Lv Z, Feng HY, Wang T, Ma X, Zhang X. Preoperative systemic inflammation response index indicates poor prognosis in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus. Urol Oncol 2022;40:167.e9-167.e19. [PMID: 35042663 DOI: 10.1016/j.urolonc.2021.11.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
96 Joshi I, Peravali M, Geng X, Rao S, Chen KY, Veytsman I, Giaccone G, Liu SV, Kim C. Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients with Advanced NSCLC Receiving First-line Pembrolizumab-based Therapy. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Serino M, Freitas C, Martins M, Ferreira P, Cardoso C, Veiga F, Santos V, Araújo D, Novais-bastos H, Magalhães A, Queiroga H, Fernandes G, Hespanhol V. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.03.003] [Reference Citation Analysis]
98 Keup C, Kimmig R, Kasimir-bauer S. Combinatorial Power of cfDNA, CTCs and EVs in Oncology. Diagnostics 2022;12:870. [DOI: 10.3390/diagnostics12040870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Han Y, Zhu Z, You Q, Granito A. The Survival Relationship between Preoperative Inflammation Markers and Patients with Special Pathological Types of Gastric Cancer. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-10. [DOI: 10.1155/2022/5715898] [Reference Citation Analysis]
100 Shahzad MH, Feng L, Su X, Brassard A, Dhoparee-Doomah I, Ferri LE, Spicer JD, Cools-Lartigue JJ. Neutrophil Extracellular Traps in Cancer Therapy Resistance. Cancers (Basel) 2022;14:1359. [PMID: 35267667 DOI: 10.3390/cancers14051359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
101 Mao S, Yu X, Sun J, Yang Y, Shan Y, Sun J, Mugaanyi J, Fan R, Wu S, Lu C. Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection. BMC Cancer 2022;22:249. [PMID: 35255845 DOI: 10.1186/s12885-022-09345-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
102 Chang B, Peng T, Wu Y, Hsieh T, Huang C. Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors. JPM 2022;12:404. [DOI: 10.3390/jpm12030404] [Reference Citation Analysis]
103 Yun TH, Jeong YY, Lee SJ, Choi YS, Ryu JM. Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors. J Clin Med 2022;11:1355. [PMID: 35268446 DOI: 10.3390/jcm11051355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Hong Y, Duan P, He L, Li Q, Chen Y, Wang P, Fu Y, Liu T, Ding Z. Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer. CMAR 2022;Volume 14:1153-64. [DOI: 10.2147/cmar.s347323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Konopka K, Frączek P, Lubaś M, Micek A, Kwinta Ł, Streb J, Potocki P, Wysocki PJ. Reduction of Cancer-Induced Thrombocytosis as a Biomarker of Improved Outcomes in Advanced Gastric Cancer. J Clin Med 2022;11:1213. [PMID: 35268305 DOI: 10.3390/jcm11051213] [Reference Citation Analysis]
106 Kaisar-iluz N, Arpinati L, Shaul ME, Mahroum S, Qaisi M, Tidhar E, Fridlender ZG. The Bilateral Interplay between Cancer Immunotherapies and Neutrophils’ Phenotypes and Sub-Populations. Cells 2022;11:783. [DOI: 10.3390/cells11050783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
107 Yin L, Zhang W, Pu D, Zhai X, Lin Y, Wu Q, Chang T, Hu J, Li Y, Zhou Q. Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis. Front Oncol 2021;11:778549. [PMID: 35186710 DOI: 10.3389/fonc.2021.778549] [Reference Citation Analysis]
108 Yoshino A, Nakamura Y, Hashiguchi S, Ishida S, Mano R, Nakamura S, Kita R, Seto M, Takata T, Ishikura H, Kondo S. The Association between the Oral-Gut Axis and the Outcomes of Severe COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation: A Case-Control Study. J Clin Med 2022;11:1167. [PMID: 35268256 DOI: 10.3390/jcm11051167] [Reference Citation Analysis]
109 Chen T, Liang G, Xiang Z, He J, Xu X, Tang M. Prognostic value of prognostic nutritional index and its variations in advanced non-small-cell lung cancer patients treated with anlotinib monotherapy. J Clin Lab Anal 2022;:e24300. [PMID: 35179795 DOI: 10.1002/jcla.24300] [Reference Citation Analysis]
110 Huang L, Jiang S, Shi Y. Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. Future Oncol 2022. [PMID: 35132871 DOI: 10.2217/fon-2021-1304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
111 Li X, Wang J, Fu J, Xie X, Xie X. Prognostic significance of preoperative serum inflammation markers in patients with male breast cancer. Transl Cancer Res 2021;10:4002-8. [PMID: 35116698 DOI: 10.21037/tcr-21-693] [Reference Citation Analysis]
112 Sonehara K, Tateishi K, Araki T, Komatsu M, Akahane J, Yamamoto H, Hanaoka M. Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. CMAR 2022;Volume 14:427-35. [DOI: 10.2147/cmar.s347852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Ma Y, Shang K, Wu S, Wang J, Cao B. The Prognostic Value of Albumin-Globulin Ratio and Eosinophil-Neutrophil Ratio in Patients with Advanced Tumors Undergoing Treatment with PD-1/PD-L1 Inhibitors. Nutr Cancer 2022;:1-14. [PMID: 35102801 DOI: 10.1080/01635581.2022.2032764] [Reference Citation Analysis]
114 Santos V, Freitas C, Fernandes MG, Sousa C, Reboredo C, Cruz-martins N, Mosquera J, Hespanhol V, Campelo R. Liquid biopsy: the value of different bodily fluids. Biomarkers in Medicine. [DOI: 10.2217/bmm-2021-0370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. [PMID: 35060536 DOI: 10.1097/MD.0000000000028617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
116 Liu D, Czigany Z, Heij LR, Bouwense SAW, van Dam R, Lang SA, Ulmer TF, Neumann UP, Bednarsch J. The Value of Platelet-to-Lymphocyte Ratio as a Prognostic Marker in Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14:438. [PMID: 35053599 DOI: 10.3390/cancers14020438] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
117 Lu P, Ma Y, Kai J, Wang J, Yin Z, Xu H, Li X, Liang X, Wei S, Liang X. A Low Advanced Lung Cancer Inflammation Index Predicts a Poor Prognosis in Patients With Metastatic Non–Small Cell Lung Cancer. Front Mol Biosci 2022;8:784667. [DOI: 10.3389/fmolb.2021.784667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Kasten-Jolly J, Lawrence DA. Differential blood leukocyte populations based on individual variances and age. Immunol Res 2022. [PMID: 35023048 DOI: 10.1007/s12026-021-09257-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Brueckl NF, Wirtz RM, Reich FPM, Veltrup E, Zeitler G, Meyer C, Wuerflein D, Ficker JH, Eidt S, Brueckl WM. Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2021;10:4106-19. [PMID: 35004242 DOI: 10.21037/tlcr-21-587] [Reference Citation Analysis]
120 Murakami Y, Tamiya A, Taniguchi Y, Adachi Y, Enomoto T, Azuma K, Inagaki Y, Kouno S, Matsuda Y, Okishio K, Atagi S. Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab. Thorac Cancer 2022. [PMID: 34989133 DOI: 10.1111/1759-7714.14303] [Reference Citation Analysis]
121 Cheng B, Ding K, Chen P, Ji J, Luo T, Guo X, Qiu W, Ma C, Meng X, Wang J, Yu J, Liu Y. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond) 2022;42:17-36. [PMID: 34981670 DOI: 10.1002/cac2.12244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
122 Zhaojun X, Xiaobin C, Juan A, Jiaqi Y, Shuyun J, Tao L, Baojia C, Cheng W, Xiaoming M. Correlation analysis between preoperative systemic immune inflammation index and prognosis of patients after radical gastric cancer surgery: based on propensity score matching method. World J Surg Oncol 2022;20:1. [PMID: 34980151 DOI: 10.1186/s12957-021-02457-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
123 Hosseini M, Rezaei N. Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_52] [Reference Citation Analysis]
124 Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2021.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Wu M, Liu J, Wu S, Liu J, Wu H, Yu J, Meng X. Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Immunol 2021;12:803247. [PMID: 34970277 DOI: 10.3389/fimmu.2021.803247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
126 Takano G, Kawakita D, Matoba T, Oguri K, Murashima A, Minohara K, Tsuge H, Matsumura A, Hojo W, Tsukamoto K, Harata I, Maseki S, Ozawa T, Mitsuya S, Moribe K, Iwasaki S. Clinical analysis of lenvatinib therapy for unresectable thyroid cancer at Nagoya City University Hospital and related facilities. Toukeibu Gan 2022;48:7-13. [DOI: 10.5981/jjhnc.48.7] [Reference Citation Analysis]
127 Siddiqui F, García-Ortega A, Kantarcioglu B, Sinacore J, Tafur A, Demelo-Rodríguez P, Antonio Nieto J, Usandizaga E, Fareed J, Monreal M, The Riete Investigators. Cellular Indices and Outcome in Patients with Acute Venous Thromboembolism. Clin Appl Thromb Hemost 2022;28:10760296221113346. [PMID: 35866197 DOI: 10.1177/10760296221113346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 胡 希. Correlation between NLR/LMR/PLR and Prognosis of Patients with Gastric Cancer. ACM 2022;12:4240-4245. [DOI: 10.12677/acm.2022.125614] [Reference Citation Analysis]
129 Ma Y, Zhu D, Shi N, Zhang L, Chen G, Ge Y, Zhang Z, Chen R, Liu S, Fan Y, Zhang H, Wang Y; Department of Infectious Disease Prevention, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China, Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China, Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University [NHC Key Lab of Health Economics and Policy Research (Shandong University)], Jinan, 250012,China, Chinese Medicine Standardization Research Center, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China, Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. . China CDC Weekly 2022;4:195-8. [DOI: 10.46234/ccdcw2022.047] [Reference Citation Analysis]
130 石 攀. Research Progress of Preoperative Immune Nutrition Score and Prognosis of Malignant Tumor. ACM 2022;12:10772-10777. [DOI: 10.12677/acm.2022.12111552] [Reference Citation Analysis]
131 Lin YW, Kang WP, Huang BL, Qiu ZH, Wei LF, Zhang B, Ding TY, Luo Y, Liu CT, Chu LY, Guo HP, Xu YW, Peng YH. Nomogram based on clinical characteristics and serological inflammation markers to predict overall survival of oral tongue squamous cell carcinoma patient after surgery. BMC Oral Health 2021;21:667. [PMID: 34961504 DOI: 10.1186/s12903-021-02028-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
132 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
133 Sonehara K, Tateishi K, Araki T, Komatsu M, Akahane J, Yamamoto H, Hanaoka M. Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series. Case Rep Oncol 2021;14:1561-6. [PMID: 34949996 DOI: 10.1159/000519597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Reijmen E, De Mey S, Van Damme H, De Ridder K, Gevaert T, De Blay E, Bouwens L, Collen C, Decoster L, De Couck M, Laoui D, De Grève J, De Ridder M, Gidron Y, Goyvaerts C. Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth. Front Immunol 2021;12:772555. [PMID: 34925341 DOI: 10.3389/fimmu.2021.772555] [Reference Citation Analysis]
135 Ruan DY, Chen YX, Wei XL, Wang YN, Wang ZX, Wu HX, Xu RH, Yuan SQ, Wang FH. Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterol Rep (Oxf) 2021;9:560-70. [PMID: 34925853 DOI: 10.1093/gastro/goab032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Liu J, Zhang S, Mi R, Chen L, Yin Q. Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis. Cancer Cell Int 2021;21:688. [PMID: 34923981 DOI: 10.1186/s12935-021-02391-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Zhao N, Ruan M, Koestler DC, Lu J, Salas LA, Kelsey KT, Platz EA, Michaud DS. Methylation-derived inflammatory measures and lung cancer risk and survival. Clin Epigenet 2021;13. [DOI: 10.1186/s13148-021-01214-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Chen X, Meng F, Jiang R. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:746976. [PMID: 34900692 DOI: 10.3389/fonc.2021.746976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
139 Benzekry S, Grangeon M, Karlsen M, Alexa M, Bicalho-Frazeto I, Chaleat S, Tomasini P, Barbolosi D, Barlesi F, Greillier L. Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. Cancers (Basel) 2021;13:6210. [PMID: 34944830 DOI: 10.3390/cancers13246210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
140 Wei LF, Huang XC, Lin YW, Luo Y, Ding TY, Liu CT, Chu LY, Xu YW, Peng YH, Guo HP. A Prognostic Model Based on Clinicopathological Features and Inflammation- and Nutrition-Related Indicators Predicts Overall Survival in Surgical Patients With Tongue Squamous Cell Carcinoma. Technol Cancer Res Treat 2021;20:15330338211043048. [PMID: 34866500 DOI: 10.1177/15330338211043048] [Reference Citation Analysis]
141 Benzekry S, Grangeon M, Karlsen M, Alexa M, Bicalho-frazeto I, Chaleat S, Tomasini P, Barbolosi D, Barlesi F, Greillier L. Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data.. [DOI: 10.1101/2021.11.30.21267064] [Reference Citation Analysis]
142 Wang Y, Chen P, Huang J, Liu M, Peng D, Li Z, Chen T, Hong S, Zhou Y. Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy. Ann Transl Med 2021;9:1801. [PMID: 35071495 DOI: 10.21037/atm-21-6578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. J Cancer Res Clin Oncol 2021. [PMID: 34825950 DOI: 10.1007/s00432-021-03866-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Zheng J, Wang H. Association Between Platelet-to-Lymphocyte Ratio and Preterm Necrotizing Enterocolitis. Front Pediatr 2021;9:686880. [PMID: 34805031 DOI: 10.3389/fped.2021.686880] [Reference Citation Analysis]
145 Ma C, Yu R, Li J, Guo J, Xu J, Wang X, Liu P. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients. J Surg Oncol 2021. [PMID: 34811745 DOI: 10.1002/jso.26757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Biswas T, Gawdi R, Jindal C, Iyer S, Kang KH, Bajor D, Machtay M, Choi YM, Efird JT. Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial. J Thorac Dis 2021;13:5617-26. [PMID: 34795912 DOI: 10.21037/jtd-21-1018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Wang Y, Lin X, Sun D. A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models? Ann Transl Med 2021;9:1597. [PMID: 34790803 DOI: 10.21037/atm-21-4733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Fan Y, Fan C, Mao P, Rui C, Wang X, Hou W, Luan T, Dong Z, Li P, Feng S, Zeng X. Study on perinatal-related factors of maternity and newborn in parturients with intrapartum fever in part of Eastern China: A cross-sectional study. J Clin Lab Anal 2021;:e24050. [PMID: 34786765 DOI: 10.1002/jcla.24050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Zheng K, Liu X, Ji W, Lu J, Cui J, Li W. The Efficacy of Different Inflammatory Markers for the Prognosis of Patients with Malignant Tumors. J Inflamm Res 2021;14:5769-85. [PMID: 34764670 DOI: 10.2147/JIR.S334941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
150 Tang Y, Cui Y, Li LL, Guan YP, Feng DF, Yin BB, Liang XF, Yin J, Jiang R, Liang J, Sun YH, Wang J. Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancer Manag Res 2021;13:8241-55. [PMID: 34754244 DOI: 10.2147/CMAR.S329963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
151 Arfsten H, Cho A, Prausmüller S, Spinka G, Novak J, Goliasch G, Bartko PE, Raderer M, Gisslinger H, Kornek G, Köstler W, Strunk G, Preusser M, Hengstenberg C, Hülsmann M, Pavo N. Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. Front Cardiovasc Med 2021;8:725903. [PMID: 34746248 DOI: 10.3389/fcvm.2021.725903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Xu Z, Wang X, Zeng S, Ren X, Yan Y, Gong Z. Applying artificial intelligence for cancer immunotherapy. Acta Pharm Sin B 2021;11:3393-405. [PMID: 34900525 DOI: 10.1016/j.apsb.2021.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
153 Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Knežević J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J Pers Med 2021;11:1102. [PMID: 34834454 DOI: 10.3390/jpm11111102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
154 Li L, Pi C, Yan X, Lu J, Yang X, Wang C, Li X, Zhang S, Zhang Z, Sun Y, Hu Y. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy. Front Oncol 2021;11:697865. [PMID: 34692478 DOI: 10.3389/fonc.2021.697865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Qi J, Zhang J, Ge X, Wang X, Xu L, Liu N, Zhao L, Wang P. The Addition of Peripheral Blood Inflammatory Indexes to Nomogram Improves the Predictive Accuracy of Survival in Limited-Stage Small Cell Lung Cancer Patients. Front Oncol 2021;11:713014. [PMID: 34692490 DOI: 10.3389/fonc.2021.713014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
156 Łochowski M, Chałubińska-Fendler J, Zawadzka I, Łochowska B, Rębowski M, Brzeziński D, Kozak J. The Prognostic Significance of Preoperative Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Operated for Non-Small Cell Lung Cancer. Cancer Manag Res 2021;13:7795-802. [PMID: 34675674 DOI: 10.2147/CMAR.S317705] [Reference Citation Analysis]
157 Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Immunotherapeutic Advances for NSCLC. Biologics 2021;15:399-417. [PMID: 34675481 DOI: 10.2147/BTT.S295406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
158 Araki T, Kitaguchi Y, Suzuki Y, Komatsu M, Sonehara K, Wada Y, Tateishi K, Hanaoka M. Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy. Thorac Cancer 2021;12:2857-64. [PMID: 34599854 DOI: 10.1111/1759-7714.14142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
159 Pinto-Paz ME, Cotrina-Concha JM, Benites-Zapata VA. Mortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio. Cancer Treat Res Commun 2021;29:100464. [PMID: 34598061 DOI: 10.1016/j.ctarc.2021.100464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Ichiki Y, Ueno M, Yanagi S, Kanasaki Y, Goto H, Fukuyama T, Mikami S, Nakanishi K, Ishida T. An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer. Transl Lung Cancer Res 2021;10:3520-37. [PMID: 34584854 DOI: 10.21037/tlcr-21-479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
161 Li YX, Chang JY, He MY, Wang HR, Luo DQ, Li FH, Li JH, Ran L. Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer. J Oncol 2021;2021:2939162. [PMID: 34539781 DOI: 10.1155/2021/2939162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
162 Sibille A, Henket M, Corhay JL, Alfieri R, Louis R, Duysinx B. White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 2021;199:549-57. [PMID: 34518898 DOI: 10.1007/s00408-021-00474-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
163 Yin W, Lv J, Yao Y, Zhao Y, He Z, Wang Q, Cui L, Dai H. Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients. Thorac Cancer 2021;12:2680-90. [PMID: 34498383 DOI: 10.1111/1759-7714.14103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 2021;6:100254. [PMID: 34481329 DOI: 10.1016/j.esmoop.2021.100254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
165 Li J, Zuo M, Zhou X, Xiang Y, Zhang S, Feng W, Liu Y. Prognostic Significance of Preoperative Albumin to Alkaline Phosphatase Ratio in Patients with Glioblastoma. J Cancer 2021;12:5950-9. [PMID: 34476009 DOI: 10.7150/jca.61866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Colloca G, Venturino A. Peripheral Blood Cell Variables Related to Systemic Inflammation in Patients With Unresectable or Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Pancreas 2021;50:1131-6. [PMID: 34714276 DOI: 10.1097/MPA.0000000000001878] [Reference Citation Analysis]
167 Zhou J, Wong AH, Wang H, Jin S, Tan F, Chen Y, He S, Shen G, Frey B, Fietkau R, Hecht M, Carr SR, Wang R, Shen B, Schrump DS, Ma H, Gaipl US. Definition of a new blood cell count (BCT) score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials.. [DOI: 10.1101/2021.08.28.21262770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
168 Konopka K, Micek A, Ochenduszko S, Streb J, Potocki P, Kwinta Ł, Wysocki PJ. Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients. J Clin Med 2021;10:3902. [PMID: 34501353 DOI: 10.3390/jcm10173902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
169 Lecot P, Ardin M, Dussurgey S, Alcazer V, Moudombi L, Hubert M, Swalduz A, Hernandez-vargas H, Viari A, Caux C, Michallet M. Gene signature of circulating platelet-bound neutrophils is associated with poor prognosis in cancer patients.. [DOI: 10.1101/2021.08.26.457803] [Reference Citation Analysis]
170 Fu F, Deng C, Wen Z, Gao Z, Zhao Y, Han H, Zheng S, Wang S, Li Y, Hu H, Zhang Y, Chen H. Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Transl Lung Cancer Res 2021;10:3144-54. [PMID: 34430354 DOI: 10.21037/tlcr-21-267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
171 Wang W, Long MM, Wei CJ, Cui XW, Ren JY, Gu YH, Li QF, Dai SD, Gu B, Wang ZC. Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases. Ann Transl Med 2021;9:1059. [PMID: 34422971 DOI: 10.21037/atm-21-542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Matsukane R, Watanabe H, Hata K, Suetsugu K, Tsuji T, Egashira N, Nakanishi Y, Okamoto I, Ieiri I. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Sci Rep 2021;11:15057. [PMID: 34301991 DOI: 10.1038/s41598-021-94336-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
173 Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N. Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer 2021;9:e002242. [PMID: 34301813 DOI: 10.1136/jitc-2020-002242] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
174 Ishibashi Y, Tsujimoto H, Sugasawa H, Kouzu K, Itazaki Y, Sugihara T, Harada M, Ito N, Kishi Y, Ueno H. Prognostic value of platelet-related measures for overall survival in esophageal squamous cell carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2021;164:103427. [PMID: 34273499 DOI: 10.1016/j.critrevonc.2021.103427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
175 Lin X, Deng H, Yang Y, Wu J, Qiu G, Li S, Xie X, Liu M, Xie Z, Qin Y, Song Y, Zhou C. Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. Front Oncol 2021;11:698832. [PMID: 34327140 DOI: 10.3389/fonc.2021.698832] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
176 Chen M, Zhu Y, Wang J, Wang G, Wu Y. The Predictive Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Levels of Diabetic Peripheral Neuropathy. J Pain Res 2021;14:2049-58. [PMID: 34267549 DOI: 10.2147/JPR.S304595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
177 Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int 2021;21:356. [PMID: 34233686 DOI: 10.1186/s12935-021-02072-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
178 Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N, Amat R, Felip E. Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. Cancers (Basel) 2021;13:3249. [PMID: 34209601 DOI: 10.3390/cancers13133249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
179 Ahn BC, So JW, Synn CB, Kim TH, Kim JH, Byeon Y, Kim YS, Heo SG, Yang SD, Yun MR, Lim S, Choi SJ, Lee W, Kim DK, Lee EJ, Lee S, Lee DJ, Kim CG, Lim SM, Hong MH, Cho BC, Pyo KH, Kim HR. Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. Eur J Cancer 2021;153:179-89. [PMID: 34182269 DOI: 10.1016/j.ejca.2021.05.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
180 Han R, Chen G, Li M, Peng ZM, Xu L. Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma. Cancer Med 2021;10:5088-100. [PMID: 34152098 DOI: 10.1002/cam4.4065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Palaia I, Tomao F, DI Pinto A, Pernazza A, Santangelo G, D'Alessandris N, Manganaro L, Arno A, Donato VD, Perniola G, Della Rocca C, Panici PB. Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors. In Vivo 2021;35:1277-83. [PMID: 33622931 DOI: 10.21873/invivo.12379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
182 Yuan C, Pan Y, Ning Y. Predictive Value of IL-6 Combined with NLR in Inflammation and Cancer. Cancer Invest 2021;39:489-504. [PMID: 34139921 DOI: 10.1080/07357907.2020.1858852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Ito Y, Onoda N, Kihara M, Miya A, Miyauchi A. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate. In Vivo 2021;35:1125-32. [PMID: 33622910 DOI: 10.21873/invivo.12358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
184 Li H, Wu X, Bai Y, Wei W, Li G, Fu M, Jie J, Wang C, Guan X, Feng Y, Meng H, Li M, He M, Zhang X, Guo H. Physical activity attenuates the associations of systemic immune-inflammation index with total and cause-specific mortality among middle-aged and older populations. Sci Rep 2021;11:12532. [PMID: 34131164 DOI: 10.1038/s41598-021-91324-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Wang N, Xi W, Lu S, Jiang J, Wang C, Zhu Z, Yan C, Liu J, Zhang J. A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy. Front Oncol 2021;11:650562. [PMID: 34195071 DOI: 10.3389/fonc.2021.650562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
186 Chen L, Zeng H, Du Z, Zhao Y, Ma X. Nomogram based on pre-treatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma. Cancer Biomark 2020;29:151-61. [PMID: 32623392 DOI: 10.3233/CBM-201739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
187 Onn A, Gottfried T, Stemmer A, Appel S, Lawrence YR, Urban D, Beller T, Daher S, Bar J. Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:2800. [PMID: 34199805 DOI: 10.3390/cancers13112800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Peng J, Dong R, Jiao J, Liu M, Zhang X, Bu H, Dong P, Zhao S, Xing N, Feng S, Yang X, Kong B. Enhanced Recovery After Surgery Impact on the Systemic Inflammatory Response of Patients Following Gynecological Oncology Surgery: A Prospective Randomized Study. Cancer Manag Res 2021;13:4383-92. [PMID: 34103993 DOI: 10.2147/CMAR.S294718] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
189 Aloe C, Wang H, Vlahos R, Irving L, Steinfort D, Bozinovski S. Emerging and multifaceted role of neutrophils in lung cancer. Transl Lung Cancer Res 2021;10:2806-18. [PMID: 34295679 DOI: 10.21037/tlcr-20-760] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
190 Sánchez-Gastaldo A, Muñoz-Fuentes MA, Molina-Pinelo S, Alonso-García M, Boyero L, Bernabé-Caro R. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. Transl Lung Cancer Res 2021;10:2509-22. [PMID: 34295658 DOI: 10.21037/tlcr-21-156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
191 Huang W, Liu P, Zong M, Chen QQ, Zhou H, Kong H, Xie WP. Combining Lactate Dehydrogenase and Fibrinogen: Potential Factors to Predict Therapeutic Efficacy and Prognosis of Patients with Small-Cell Lung Cancer. Cancer Manag Res 2021;13:4299-307. [PMID: 34103985 DOI: 10.2147/CMAR.S300153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Lenci E, Marcantognini G, Cognigni V, Lupi A, Rinaldi S, Cantini L, Fiordoliva I, Carloni AL, Rocchi M, Zuccatosta L, Gasparini S, Berardi R. Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Zhao N, Ruan M, Koestler DC, Lu J, Kelsey KT, Platz EA, Michaud DS. Methylation-derived Inflammatory Measures and Lung Cancer Risk and Survival.. [DOI: 10.1101/2021.05.24.21257709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Guo Z, Liang J. Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy. Cancer Manag Res 2021;13:4169-80. [PMID: 34079370 DOI: 10.2147/CMAR.S307272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer 2021;151:211-20. [PMID: 34022698 DOI: 10.1016/j.ejca.2021.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
196 Liu K, Jiang G, Fang N, Cai L, Du W, Jia J. Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. J Int Med Res 2020;48:300060520980205. [PMID: 33350871 DOI: 10.1177/0300060520980205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
197 Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C, Manacorda S, Maruzzo M, Milella M, Buttigliero C, Tambaro R, Ermacora P, Morelli F, Nolè F, Astolfi C, Sternberg CN. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open 2021;6:100118. [PMID: 33984678 DOI: 10.1016/j.esmoop.2021.100118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
198 Yuan X, Zheng Z, Liu F, Gao Y, Zhang W, Berardi R, Mohindra P, Zhu Z, Lin J, Chu Q. A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy. Transl Lung Cancer Res 2021;10:2163-71. [PMID: 34164267 DOI: 10.21037/tlcr-21-211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Kirlangiç MM, Sade O, Vural M, Akdemir E. Evaluation of third-trimester neutrophil-lymphocyte and platelet-lymphocyte ratios and their correlation with birth weight. Journal of Surgery and Medicine 2021;5:508-511. [DOI: 10.28982/josam.918863] [Reference Citation Analysis]
200 Winarno GNA, Pasaribu M, Susanto H, Nisa AS, Harsono AB, Yuseran H, Suardi D, Trianasari N. The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer. Asian Pac J Cancer Prev 2021;22:1561-6. [PMID: 34048186 DOI: 10.31557/APJCP.2021.22.5.1561] [Reference Citation Analysis]
201 Park CK, Oh HJ, Kim MS, Koh BG, Cho HJ, Kim YC, Yang HJ, Lee JY, Chun SM, Oh IJ. Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2103-17. [PMID: 34164263 DOI: 10.21037/tlcr-21-100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
202 Jiang H, Jiang W, Tan L, Yu Q, Liu F, Huang Y, He J, Zhou S. The predictive value of pretreatment haemoglobin-to-red cell distribution width ratio for overall survival of patients with advanced non-small cell lung cancer: a propensity score matching analysis. J Int Med Res 2021;49:3000605211004229. [PMID: 33823630 DOI: 10.1177/03000605211004229] [Reference Citation Analysis]
203 Shi X, Fan J, Pei X, Wang Y, Guo G, Yang T, Wang X, He D, Li L. Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel. Andrologia 2021;53:e14064. [PMID: 33900646 DOI: 10.1111/and.14064] [Reference Citation Analysis]
204 Hata H, Mio T, Yamashita D, Matsumura C, Chisaki Y, Motohashi H, Yano Y. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. Cancer Control 2020;27:1073274820977200. [PMID: 33297768 DOI: 10.1177/1073274820977200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
205 Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC, Liu JJ, Schadt EE, Chen R, Li SD. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer 2021;21:441. [PMID: 33882890 DOI: 10.1186/s12885-021-08194-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
206 Ravindranathan D, Master VA, Bilen MA. Inflammatory Markers in Cancer Immunotherapy. Biology (Basel) 2021;10:325. [PMID: 33924623 DOI: 10.3390/biology10040325] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
207 Ding R, Zhou X, Huang D, Wang Y, Li X, Yan L, Lu W, Yang Z, Zhang Z. Predictive Performances of Blood Parameter Ratios for Liver Inflammation and Advanced Liver Fibrosis in Chronic Hepatitis B Infection. Biomed Res Int 2021;2021:6644855. [PMID: 33937406 DOI: 10.1155/2021/6644855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Lauko A, Thapa B, Sharma M, Muhsen B, Barnett A, Rauf Y, Borghei-Razavi H, Tatineni V, Patil P, Mohammadi A, Chao S, Murphy ES, Angelov L, Suh J, Barnett GH, Nowacki AS, Pennell N, Ahluwalia MS. Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. Sci Rep 2021;11:7490. [PMID: 33820922 DOI: 10.1038/s41598-021-85328-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
209 Cheng Y, Mo F, Li Q, Han X, Shi H, Chen S, Wei Y, Wei X. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. Mol Cancer 2021;20:62. [PMID: 33814009 DOI: 10.1186/s12943-021-01355-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 19.5] [Reference Citation Analysis]
210 Nøst TH, Holden M, Dønnem T, Bøvelstad H, Rylander C, Lund E, Sandanger TM. Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis. Sci Rep 2021;11:7406. [PMID: 33795786 DOI: 10.1038/s41598-021-86879-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
211 Feng Y, Liu Y, Zhong M, Wang L. Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma. Front Oncol 2021;11:618694. [PMID: 33842320 DOI: 10.3389/fonc.2021.618694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
212 Ma Y, Li G, Li X, Gao Y, Ding T, Yang G, Zhang Y, Nian J, Yu M, Wang X. Clinical characteristics and prognostic analysis of Lung Cancer patients with Hypercoagulability: A single-center, retrospective, real-world study. J Cancer 2021;12:2968-74. [PMID: 33854597 DOI: 10.7150/jca.46600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Castello A, Rossi S, Toschi L, Lopci E. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. J Clin Med 2021;10:1251. [PMID: 33803006 DOI: 10.3390/jcm10061251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
214 Du F, Qiu Z, Ai W, Huang C, Ji J, Xiao X, Zhou J, Fang M, Jiang X, Gao C. Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer. J Leukoc Biol 2021;110:327-34. [PMID: 33724548 DOI: 10.1002/JLB.5MA1220-631R] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
215 Lee PY, Oen KQX, Lim GRS, Hartono JL, Muthiah M, Huang DQ, Teo FSW, Li AY, Mak A, Chandran NS, Tan CL, Yang P, Tai ES, Ng KWP, Vijayan J, Chan YC, Tan LL, Lee MB, Chua HR, Hong WZ, Yap ES, Lim DK, Yuen YS, Chan YH, Aminkeng F, Wong ASC, Huang Y, Tay SH. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. Cancers (Basel) 2021;13:1308. [PMID: 33804050 DOI: 10.3390/cancers13061308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
216 Li L, Tian J, Zhang L, Liu L, Sheng C, Huang Y, Zheng H, Song F, Chen K. Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses. J Cancer 2021;12:2687-93. [PMID: 33854628 DOI: 10.7150/jca.51642] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
217 Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, Nicolardi L, Caglio A, Aerts S, Cortellini A, Ficorella C, Chiari R, Di Maio M, Dingemans AC, Aerts JGJV, Berardi R. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. J Clin Med 2021;10:1005. [PMID: 33801320 DOI: 10.3390/jcm10051005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
218 Zhong X, Ma A, Zhang Z, Liu Y, Liang G. Neutrophil-to-lymphocyte ratio as a predictive marker for severe pediatric sepsis. Transl Pediatr 2021;10:657-65. [PMID: 33880335 DOI: 10.21037/tp-21-47] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
219 Kinay T, Akgul MA, Kiykac Altinbas S, Tapisiz OL, Kayikcioglu F, Moraloglu Tekin O. Diagnostic value of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in adnexal torsion cases. J Obstet Gynaecol Res 2021;47:1846-53. [PMID: 33650213 DOI: 10.1111/jog.14715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
220 Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V, Fernandes G, Magalhães A, Hespanhol V, Queiroga H. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs 2021;32:567-74. [PMID: 33661189 DOI: 10.1097/CAD.0000000000001060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 You Q, Fang T, Yin X, Wang Y, Yang Y, Zhang L, Xue Y. Serum CD4 Is Associated with the Infiltration of CD4+T Cells in the Tumor Microenvironment of Gastric Cancer. J Immunol Res 2021;2021:6539702. [PMID: 34258299 DOI: 10.1155/2021/6539702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Sumiyoshi I, Okabe T, Togo S, Takagi H, Motomura H, Ochi Y, Shimada N, Haraguchi M, Shibayama R, Fujimoto Y, Watanabe J, Iwai M, Kadoya K, Iwakami SI, Takahashi K. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. J Transl Med 2021;19:92. [PMID: 33639962 DOI: 10.1186/s12967-021-02761-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Li WC, Wang Z, Gao J, Zhou H, Li J, Zhu XX. Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer. Cancer Manag Res 2021;13:1887-96. [PMID: 33654433 DOI: 10.2147/CMAR.S287993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
224 Ma Y, Zhang J, Chen X. Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancer Manag Res 2021;13:1571-80. [PMID: 33623436 DOI: 10.2147/CMAR.S292048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
225 Tsao SM, Wu TC, Chen J, Chang F, Tsao T. Astragalus Polysaccharide Injection (PG2) Normalizes the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Lung Cancer Receiving Immunotherapy. Integr Cancer Ther 2021;20:1534735421995256. [PMID: 33583212 DOI: 10.1177/1534735421995256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
226 Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, Ghanim B. Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers (Basel) 2021;13:658. [PMID: 33562138 DOI: 10.3390/cancers13040658] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
227 Hino S, Yamada M, Iijima Y, Ohmuro M, Araki R, Kaneko T, Odaka A, Iizuka T, Horie N. Change of body composition, physical strength, and nutritional status of patients with mandibular fractures. J Craniomaxillofac Surg 2021;49:292-7. [PMID: 33589334 DOI: 10.1016/j.jcms.2021.01.023] [Reference Citation Analysis]
228 Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K, Shirakawa T, Otsuka T, Ohmura H, Isobe T, Ariyama H, Koreishi S, Matsushita Y, Shimokawa H, Tanaka R, Mitsugi K, Akashi K, Baba E. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. Sci Rep 2021;11:2741. [PMID: 33531609 DOI: 10.1038/s41598-021-82448-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
229 Alfandari L, Pariente G, Yohay D, Levy O, Weintraub AY, Rotem R. Easily generated hematological biomarkers and prediction of placental abruption. J Gynecol Obstet Hum Reprod 2021;50:102082. [PMID: 33545414 DOI: 10.1016/j.jogoh.2021.102082] [Reference Citation Analysis]
230 Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy. Acta Oncol 2021;60:149-56. [PMID: 33356733 DOI: 10.1080/0284186X.2020.1854851] [Reference Citation Analysis]
231 Bittoni A, Pecci F, Mentrasti G, Crocetti S, Lupi A, Lanese A, Pellei C, Ciotti C, Cantini L, Giampieri R, Lenci E, Giglio E, Bini F, Copparoni C, Meletani T, Baleani MG, Berardi R. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Ann Transl Med 2021;9:251. [PMID: 33708878 DOI: 10.21037/atm-20-3499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
232 Chen C, Yang H, Cai D, Xiang L, Fang W, Wang R. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res 2021;10:866-77. [PMID: 33718028 DOI: 10.21037/tlcr-20-997] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
233 Petrioli R, Mazzei MA, Giorgi S, Cesqui E, Gentili F, Francini G, Volterrani L, Francini E. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study. Anticancer Drugs 2020;31:190-5. [PMID: 31850916 DOI: 10.1097/CAD.0000000000000864] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
234 Liu W, Liu Y, Ma F, Sun B, Wang Y, Luo J, Liu M, Luo Z. Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Manag Res 2021;13:765-71. [PMID: 33536784 DOI: 10.2147/CMAR.S293200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
235 Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Sci Rep 2021;11:1324. [PMID: 33446685 DOI: 10.1038/s41598-020-79397-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
236 Cheng X, Dong Y, Lou F. The Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy. Cancer Manag Res 2021;13:173-80. [PMID: 33469361 DOI: 10.2147/CMAR.S286453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
237 Kim SR, Chun SH, Kim JR, Kim SY, Seo JY, Jung CK, Gil BM, Kim JO, Ko YH, Woo IS, Shim BY, Hong SH, Kang JH. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. BMC Cancer 2021;21:19. [PMID: 33402127 DOI: 10.1186/s12885-020-07727-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
238 Ishihara M, Ochiai R, Haruyama T, Sakamoto T, Tanzawa S, Honda T, Ota S, Ichikawa Y, Ishida T, Watanabe K, Seki N. Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2021;10:221-32. [PMID: 33569306 DOI: 10.21037/tlcr-20-777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
239 张 杰. Relationship between NLR and Efficacy of First-Line Chemotherapy for Chronic Obstructive Pulmonary Disease with Lung Cancer. ACM 2021;11:403-409. [DOI: 10.12677/acm.2021.111057] [Reference Citation Analysis]
240 Ksienski D, Wai ES, Alex D, Croteau NS, Freeman AT, Chan A, Patterson T, Clarkson M, Fiorino L, Poonja Z, Fenton D, Irons S, Lesperance M. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Transl Lung Cancer Res 2021;10:355-67. [PMID: 33569318 DOI: 10.21037/tlcr-20-541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
241 Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z, Zhou L. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg 2021;25:421-7. [PMID: 32026332 DOI: 10.1007/s11605-019-04492-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 18.0] [Reference Citation Analysis]
242 Gao ZY, Zhang T, Zhang H, Pang CG, Jiang WX. Establishment and validation of nomogram model for survival predicting in patients with spinal metastases secondary to lung cancer. Neurol Res 2021;43:327-35. [PMID: 33377432 DOI: 10.1080/01616412.2020.1866244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Peng SM, Yu N, Ren JJ, Xu JY, Chen GC, Yang JR, Li ZN, Du HZ, Li DP, Zhang YS, Qin LQ. The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Non-Small-Cell Lung Cancer. Nutr Cancer 2020;:1-10. [PMID: 33356605 DOI: 10.1080/01635581.2020.1865423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
244 Üçsular F, Polat G, Karadeniz G, Ayranci A, Keskin M, Buyukşirin M, Güldaval F, Yalniz E. Predictive value of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with hypersensitivity pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:e2020012. [PMID: 33597799 DOI: 10.36141/svdld.v37i4.9966] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Li Z, Qu Y, Yang Y, An W, Li S, Wang B, He Y, Li J, Shao Q, Qin L. Prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with laryngeal squamous cell carcinoma. Clin Otolaryngol 2021;46:395-405. [PMID: 33321001 DOI: 10.1111/coa.13689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
246 Sun W, Gao M, Hu G, Yuan X. Inflammatory Marker Predicts Outcome of Oral Squamous Cell Carcinoma Receiving Chemo-Radiotherapy. Cancer Manag Res 2020;12:12329-35. [PMID: 33293860 DOI: 10.2147/CMAR.S277927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
247 Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med 2021;10:247-56. [PMID: 33300678 DOI: 10.1002/cam4.3631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
248 Erdogan T. Role of systemic immune-inflammation index in asthma and NSAID-exacerbated respiratory disease. Clin Respir J 2021;15:400-5. [PMID: 33249745 DOI: 10.1111/crj.13314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
249 Petrella F, Casiraghi M, Radice D, Prisciandaro E, Rizzo S, Spaggiari L. Prognostic Value of Red Blood Cell Distribution Width in Resected pN1 Lung Adenocarcinoma. Cancers (Basel) 2020;12:E3677. [PMID: 33302343 DOI: 10.3390/cancers12123677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
250 Guida A, Le Teuff G, Alves C, Colomba E, Di Nunno V, Derosa L, Flippot R, Escudier B, Albiges L. Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget 2020;11:4582-92. [PMID: 33346231 DOI: 10.18632/oncotarget.27762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
251 He X, Jiao YQ, Yang XG, Hu YC. A Novel Prediction Tool for Overall Survival of Patients Living with Spinal Metastatic Disease. World Neurosurg 2020;144:e824-36. [PMID: 32956891 DOI: 10.1016/j.wneu.2020.09.081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
252 Li TC, Wang LL, Liu BL, Hong JJ, Xu NN, Tang K, Zheng XW. Association between bone marrow fluorodeoxyglucose uptake and recurrence after curative surgical resection in patients with T1-2N0M0 lung adenocarcinoma: a retrospective cohort study. Quant Imaging Med Surg 2020;10:2285-96. [PMID: 33269227 DOI: 10.21037/qims-19-962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
253 Wojas-Krawczyk K, Kubiatowski T. Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research. Front Oncol 2020;10:568174. [PMID: 33330041 DOI: 10.3389/fonc.2020.568174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
254 Bingöl Tanrıverdi T, Tercan M, Güsun Halitoğlu A, Kaya A, Patmano G. Comparison of the Effects of Low-flow and Normal-flow Desflurane Anaesthesia on Inflammatory Parameters in Patients Undergoing Laparoscopic Cholecystectomy. Turk J Anaesthesiol Reanim 2021;49:18-24. [PMID: 33718901 DOI: 10.5152/TJAR.2020.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
255 Wang C, Ding Y, Liu Y, Zhang Q, Xu S, Xia L, Duan H, Wang S, Ji P, Huang W, Zhao G, Cao Z, Shen H, Wang Y. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation. Front Immunol 2020;11:576603. [PMID: 33329543 DOI: 10.3389/fimmu.2020.576603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Yu Y, Zheng P, Gao L, Li H, Tao P, Wang D, Ding F, Shi Q, Chen H. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. J Immunother 2021;44:76-85. [PMID: 33208635 DOI: 10.1097/CJI.0000000000000346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
257 Chen S, Huang H, Liu Y, Lai C, Peng S, Zhou L, Chen H, Xu Y, He X. A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection. Cancer Cell Int 2020;20:555. [PMID: 33292228 DOI: 10.1186/s12935-020-01635-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
258 Zhao C, Wang Y, Cai X, Xu W, Wang D, Wang T, Jia Q, Gong H, Sun H, Wu Z, Xiao J. Prognostic Significance of a Novel Score Model Based on Preoperative Indicators in Patients with Breast Cancer Spine Metastases (BCSM). Cancer Manag Res 2020;12:11501-13. [PMID: 33204161 DOI: 10.2147/CMAR.S273785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
259 Şahİn B, Akyol M, Özel HE, GenÇ S. Correlation of Clinical and Pathological Diagnosis and Inflammatory Markers for Patients Undergoing Laryngeal Microsurgery. J Voice 2020:S0892-1997(20)30377-5. [PMID: 33158692 DOI: 10.1016/j.jvoice.2020.10.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Ohri N, Halmos B, Bodner WR, Cheng H, Garg MK, Gucalp R, Guha C. Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis. Pract Radiat Oncol 2021;11:e172-9. [PMID: 33127337 DOI: 10.1016/j.prro.2020.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
261 Hallqvist A, Rohlin A, Raghavan S. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer. Scand J Immunol 2020;92:e12980. [PMID: 33015859 DOI: 10.1111/sji.12980] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
262 Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. Cancers (Basel) 2020;12:E2984. [PMID: 33076397 DOI: 10.3390/cancers12102984] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
263 Katayama Y, Yamada T, Chihara Y, Tanaka S, Tanimura K, Okura N, Hirose K, Uda S, Shiotsu S, Hirai S, Hiranuma O, Harada T, Shimamoto T, Iwasaku M, Kaneko Y, Uchino J, Takeda T, Takayama K. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. Sci Rep 2020;10:17495. [PMID: 33060826 DOI: 10.1038/s41598-020-74573-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
264 Verhaart SL, Abu-Ghanem Y, Mulder SF, Oosting S, Van Der Veldt A, Osanto S, Aarts MJB, Houtsma D, Peters FPJ, Groenewegen G, Van Herpen CML, Pronk LM, Tascilar M, Hamberg P, Los M, Vreugdenhil G, Polee M, Ten Tije AJ, Haanen JBAG, Bex A, van den Eertwegh AJ. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clin Genitourin Cancer 2021;19:274.e1-274.e16. [PMID: 33317946 DOI: 10.1016/j.clgc.2020.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
265 Sesma A, Pardo J, Cruellas M, Gálvez EM, Gascón M, Isla D, Martínez-Lostao L, Ocáriz M, Paño JR, Quílez E, Ramírez A, Torres-Ramón I, Yubero A, Zapata M, Lastra R. From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. Cancers (Basel) 2020;12:E2974. [PMID: 33066479 DOI: 10.3390/cancers12102974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
266 Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, Fushimi C, Masubuchi T, Miura K, Okazaki SI, Matsui H, Okada T, Iwaki S, Matsuki T, Hanyu K, Tsukahara K, Oridate N, Tada Y. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep 2020;10:16988. [PMID: 33046752 DOI: 10.1038/s41598-020-73965-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
267 Wang W, Huang Z, Yu Z, Zhuang W, Zheng W, Cai Z, Shi L, Yu X, Lou G, Hong W, Zhang Y, Chen M, Song Z. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. Front Oncol 2020;10:572853. [PMID: 33163403 DOI: 10.3389/fonc.2020.572853] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
268 Mansour R, Abu-Shawer O, Lattouf A, Sultan H, Al-Hussaini M. Hematological Indices of Distant Metastases and Prognostic Nomogram in Gastro-Pancreatic and Biliary Tract Cancers. Cancer Manag Res 2020;12:9775-86. [PMID: 33116837 DOI: 10.2147/CMAR.S259197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
269 Choi MG, Kim YJ, Lee JC, Rho JK, Choi CM. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. Thorac Cancer 2020;11:3337-45. [PMID: 33017518 DOI: 10.1111/1759-7714.13677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
270 Xia WY, Zhu XR, Feng W, Liu J, Wang JM, Lv CX, Zhang Q, Yu W, Cai XW, Fu XL. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy. Transl Lung Cancer Res 2020;9:1996-2007. [PMID: 33209619 DOI: 10.21037/tlcr-20-831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
271 Ucuz İ, Kayhan Tetik B. Can suicide behavior and seasonality of suicide be predicted from inflammatory parameters in adolescents? Medical Hypotheses 2020;143:110061. [DOI: 10.1016/j.mehy.2020.110061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
272 Kawahara T, Kato M, Tabata K, Kojima I, Yamada H, Kamihira O, Tsumura H, Iwamura M, Uemura H, Miyoshi Y. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. BMC Cancer 2020;20:919. [PMID: 32977754 DOI: 10.1186/s12885-020-07410-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
273 Rojko L, Megyesfalvi Z, Czibula E, Reiniger L, Teglasi V, Szegedi Z, Szallasi Z, Dome B, Moldvay J. Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients. Thorac Cancer 2020;11:3193-204. [PMID: 32941706 DOI: 10.1111/1759-7714.13642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
274 Carnio S, Mariniello A, Pizzutilo P, Numico G, Borra G, Lunghi A, Soto Parra H, Buosi R, Vavalà T, Stura I, Genestroni S, Alemanni A, Arizio F, Catino A, Montrone M, Tabbò F, Galetta D, Migliaretti G, Novello S. ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients. JMP 2020;1:19-31. [DOI: 10.3390/jmp1010004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
275 Xiong Q, Huang Z, Xin L, Qin B, Zhao X, Zhang J, Shi W, Yang B, Zhang G, Hu Y. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. Cancer Immunol Immunother 2021;70:713-20. [PMID: 32910245 DOI: 10.1007/s00262-020-02706-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
276 Alex F, Alfredo A. Promising predictors of checkpoint inhibitor response in NSCLC. Expert Rev Anticancer Ther 2020;20:931-7. [PMID: 32870120 DOI: 10.1080/14737140.2020.1816173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
277 Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation. Clinical Lung Cancer 2020;21:e337-48. [DOI: 10.1016/j.cllc.2020.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
278 Kim Y, Oremus M, Chen HH, Mcfarlane T, Shah D, Horton S. Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncology 2020;16:2045-58. [DOI: 10.2217/fon-2020-0248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
279 Petrova MP, Donev IS, Radanova MA, Eneva MI, Dimitrova EG, Valchev GN, Minchev VT, Taushanova MS, Boneva MV, Karanikolova TS, Gencheva RB, Zhbantov GA, Ivanova AI, Timcheva CV, P Pavlov B, Megdanova VG, Robev BS, Conev NV. Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clin Exp Immunol 2020;202:353-62. [PMID: 32757277 DOI: 10.1111/cei.13505] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
280 Ding S, Ma J, Song X, Dong X, Xie L, Song X, Liu L. Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy. J Oncol 2020;2020:2192378. [PMID: 32908505 DOI: 10.1155/2020/2192378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
281 Kakhki RD, Dehghanei M, ArefNezhad R, Motedayyen H. The Predicting Role of Neutrophil- Lymphocyte Ratio in Patients with Acute Ischemic and Hemorrhagic Stroke. J Stroke Cerebrovasc Dis 2020;29:105233. [PMID: 33066938 DOI: 10.1016/j.jstrokecerebrovasdis.2020.105233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
282 Travert C, Barlesi F, Greillier L, Tomasini P. Immune Oncology Biomarkers in Lung Cancer: an Overview. Curr Oncol Rep 2020;22:107. [PMID: 32803433 DOI: 10.1007/s11912-020-00970-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
283 Kaino Y, Kitazawa F, Maeno Y, Oi T, Banno R, Nakakura I, Nakamura T, Tsujikawa M. Influence of Antibiotics on the Antitumor Effect of Immune Checkpoint Inhibitors in Japanese Patients with Non-small-cell Lung Cancer. Jpn J Pharm Health Care Sci 2020;46:436-446. [DOI: 10.5649/jjphcs.46.436] [Reference Citation Analysis]
284 Shihab I, Khalil BA, Elemam NM, Hachim IY, Hachim MY, Hamoudi RA, Maghazachi AA. Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. Cancers (Basel) 2020;12:E2226. [PMID: 32784928 DOI: 10.3390/cancers12082226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
285 Qiu Z, Jiang Y, Jiang X, Yang R, Wu Y, Xu Y, Cheng X. Relationship Between Platelet to Lymphocyte Ratio and Stable Coronary Artery Disease: Meta-Analysis of Observational Studies. Angiology 2020;71:909-15. [PMID: 32720814 DOI: 10.1177/0003319720943810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
286 Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Front Immunol 2020;11:1590. [PMID: 32793228 DOI: 10.3389/fimmu.2020.01590] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
287 Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer 2020;20:485-503. [PMID: 32694624 DOI: 10.1038/s41568-020-0281-y] [Cited by in Crossref: 229] [Cited by in F6Publishing: 248] [Article Influence: 76.3] [Reference Citation Analysis]
288 Sun L, Hu W, Liu M, Chen Y, Jin B, Xu H, Du S, Xu Y, Zhao H, Lu X, Sang X, Zhong S, Yang H, Mao Y. High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China. Cancer Res Treat 2020;52:1199-210. [PMID: 32718144 DOI: 10.4143/crt.2020.303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
289 Rapoport BL, Theron AJ, Vorobiof DA, Langenhoven L, Hall JM, Van Eeden RI, Smit T, Chan SW, Botha MC, Raats JI, Necker M, Anderson R. Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. Lung Cancer Manag 2020;9:LMT37. [PMID: 32774468 DOI: 10.2217/lmt-2020-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
290 Li A, Mu X, He K, Wang P, Wang D, Liu C, Yu J. Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases. Future Oncol 2020;16:2433-44. [PMID: 32664750 DOI: 10.2217/fon-2020-0423] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
291 Zeng X, Liu G, Pan Y, Li Y. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med 2020;24:8326-49. [PMID: 32603520 DOI: 10.1111/jcmm.15097] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
292 Jiang M, Peng W, Pu X, Chen B, Li J, Xu F, Liu L, Xu L, Xu Y, Cao J, Wang Q, Li K, Wang J, Wu L. Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy. Front Oncol 2020;10:913. [PMID: 32695663 DOI: 10.3389/fonc.2020.00913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
293 Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G, Chen R, Jiao S, Wang J. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 2020;10:654. [PMID: 32656072 DOI: 10.3389/fonc.2020.00654] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
294 Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, Thouvenin J, Barthelemy P, Thibault C, Tartour E, Oudard S, Vano YA. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother 2020;69:2513-22. [PMID: 32561968 DOI: 10.1007/s00262-020-02637-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
295 Patel A, Ravaud A, Motzer RJ, Pantuck AJ, Staehler M, Escudier B, Martini JF, Lechuga M, Lin X, George DJ. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. Clin Cancer Res 2020;26:4863-8. [PMID: 32546645 DOI: 10.1158/1078-0432.CCR-20-0704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
296 Rossi S, Toschi L, Finocchiaro G, Santoro A. Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy 2020;12:715-24. [PMID: 32522052 DOI: 10.2217/imt-2019-0154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
297 Tatsumi A, Maekawa Y, Komori Y, Yamamoto K, Hamaguchi T, Takahashi K, Kunimasa J. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive Factors for Serious Nivolumab-Induced Immune-Related Adverse Events. Jpn J Pharm Health Care Sci 2020;46:331-339. [DOI: 10.5649/jjphcs.46.331] [Reference Citation Analysis]
298 Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol 2020;85:106677. [PMID: 32531712 DOI: 10.1016/j.intimp.2020.106677] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
299 Carlisle JW, Jansen CS, Bilen MA, Kissick H. Considerations for cancer immunotherapy biomarker research during COVID-19. Endocr Relat Cancer 2020;27:C1-8. [PMID: 32508308 DOI: 10.1530/ERC-20-0187] [Reference Citation Analysis]
300 Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open 2020;10:e035031. [PMID: 32499266 DOI: 10.1136/bmjopen-2019-035031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
301 Dharmapuri S, Özbek U, Lin JY, Sung M, Schwartz M, Branch AD, Ang C. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med 2020;9:4962-70. [PMID: 32419290 DOI: 10.1002/cam4.3135] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
302 Takada K, Takamori S, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Oba T, Osoegawa A, Tagawa T, Takenoyama M, Oda Y, Nakanishi Y, Mori M. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer 2020;145:18-26. [PMID: 32388276 DOI: 10.1016/j.lungcan.2020.04.034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
303 Deng Y, Li W, Liu X, Ma G, Wu Q, Chen F, Wang Z, Zhou Q. The combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients with resected breast cancer. Medicine (Baltimore) 2020;99:e18755. [PMID: 32358341 DOI: 10.1097/MD.0000000000018755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
304 He H, Guo W, Song P, Liu L, Zhang G, Wang Y, Qiu B, Tan F, Xue Q, Gao S. Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection. Ann Transl Med 2020;8:630. [PMID: 32566567 DOI: 10.21037/atm-19-4476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
305 Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, Longo L, Zullo L, Tanda ET, Dellepiane C, Pronzato P, Genova C. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers (Basel) 2020;12:E1125. [PMID: 32365882 DOI: 10.3390/cancers12051125] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
306 Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother 2020;69:1813-22. [PMID: 32350592 DOI: 10.1007/s00262-020-02585-w] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 20.0] [Reference Citation Analysis]
307 Gerratana L, Basile D, Toffoletto B, Bulfoni M, Zago S, Magini A, Lera M, Pelizzari G, Parisse P, Casalis L, Vitale MG, Fanotto V, Bonotto M, Caponnetto F, Bartoletti M, Lisanti C, Minisini AM, Emiliani C, Di Loreto C, Fasola G, Curcio F, Beltrami AP, Cesselli D, Puglisi F. Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Sci Rep 2020;10:7010. [PMID: 32332763 DOI: 10.1038/s41598-020-63291-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
308 Yamada T, Hayashi T, Inokuchi Y, Hayashi K, Watanabe H, Komori K, Kano K, Shimoda Y, Fujikawa H, Shiozawa M, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy. Targ Oncol 2020;15:317-25. [DOI: 10.1007/s11523-020-00716-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
309 Zhou J, Jiang S, Wang W, Liu R. [Research Progress of Tumor-Associated Neutrophils and Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:727-31. [PMID: 31771743 DOI: 10.3779/j.issn.1009-3419.2019.11.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
310 Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Target Oncol 2019;14:453-63. [PMID: 31359231 DOI: 10.1007/s11523-019-00660-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
311 Zheng C, Liu S, Feng J, Zhao X. Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma. Cancer Manag Res 2020;12:2415-25. [PMID: 32280277 DOI: 10.2147/CMAR.S245622] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
312 Hwang I, Park I, Yoon S, Lee JL. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. Clinical Genitourinary Cancer 2020;18:e122-33. [DOI: 10.1016/j.clgc.2019.09.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
313 Luzo ACM, Fávaro WJ, Seabra AB, Durán N. What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review. Heliyon 2020;6:e03660. [PMID: 32258495 DOI: 10.1016/j.heliyon.2020.e03660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
314 Zhao G, Liu N, Wang S, Guo J, Song X, Qi Y, Qiu W, Lv J. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Medicine (Baltimore) 2020;99:e19405. [PMID: 32150090 DOI: 10.1097/MD.0000000000019405] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
315 Jiang Y, Zhao X, Fu J, Wang H. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. Front Immunol 2020;11:339. [PMID: 32226426 DOI: 10.3389/fimmu.2020.00339] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
316 Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, Catino A, Galetta D. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. Clin Lung Cancer 2020;21:365-377.e5. [PMID: 32245624 DOI: 10.1016/j.cllc.2019.11.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
317 Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, Nakamura K, Komiya A, Nakatsu H, Ichikawa T. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate 2020;80:559-69. [PMID: 32134137 DOI: 10.1002/pros.23969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
318 Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadrini S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Adv Ther 2020;37:1145-55. [PMID: 32002809 DOI: 10.1007/s12325-020-01229-w] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 18.7] [Reference Citation Analysis]
319 Shabto JM, Martini DJ, Liu Y, Ravindranathan D, Brown J, Hitron EE, Russler GA, Caulfield S, Kissick H, Alemozaffar M, Ogan K, Harris WB, Master VA, Kucuk O, Carthon BC, Bilen MA. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer Med 2020;9:2752-60. [PMID: 32100417 DOI: 10.1002/cam4.2932] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
320 Hu JJ, Nie SM, Gao Y, Yan XS, Huang JX, Li TL, Liu SS, Mao CX, Zhou JJ, Xu YJ, Wang W, Meng FJ, Feng XQ. [The correlations and prognostic value of neutrophil to lymphocyte ratio, immunophenotype and cytogenetic abnormalities in patients with newly diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:1044-6. [PMID: 32023739 DOI: 10.3760/cma.j.issn.0253-2727.2019.12.015] [Reference Citation Analysis]
321 Bonaventura A, Grossi F, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F. Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. Clin Transl Oncol 2020;22:1603-10. [DOI: 10.1007/s12094-020-02305-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis 2020;23:220-31. [PMID: 32034294 DOI: 10.1038/s41391-020-0209-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
323 Shi M, Zhao W, Zhou F, Chen H, Tang L, Su B, Zhang J. Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer Res 2020;9:45-54. [PMID: 32206552 DOI: 10.21037/tlcr.2020.01.17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
324 Lee W, Chan I, Wang P. Does a simple hematological examination predict the response and side effects in patients undergoing induction chemotherapy and/or neoadjuvant chemotherapy? Journal of the Chinese Medical Association 2020;83:107-8. [DOI: 10.1097/jcma.0000000000000239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
325 Tashima Y, Kuwata T, Yoneda K, Hirai A, Mori M, Kanayama M, Imanishi N, Kuroda K, Ichiki Y, Tanaka F. Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung. Sci Rep 2020;10:1243. [PMID: 31988315 DOI: 10.1038/s41598-019-57321-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
326 Wattenberg MM, Beatty GL. Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Semin Cancer Biol 2020;65:38-50. [PMID: 31954172 DOI: 10.1016/j.semcancer.2020.01.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
327 Li X, Hu P, Liu J, Zhang J, Liu Q. Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol 2020;16:103-15. [PMID: 31933380 DOI: 10.2217/fon-2019-0761] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
328 Doi H, Kuribayashi K, Kitajima K, Yamakado K, Kijima T. Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma. Clinical Lung Cancer 2020;21:66-74.e2. [DOI: 10.1016/j.cllc.2019.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
329 Mehra R. Reevaluating how we define inflammation in head-and-neck cancers. Cancer Res Stat Treat 2020;3:564. [DOI: 10.4103/crst.crst_230_20] [Reference Citation Analysis]
330 Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vollome G, Sini C, Grassi M, Dal bello M, Coco S, Longo L, Zullo L, Tanda E, Dellepiane C, Pronzato P, Genova C. Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. Kompass Pneumol 2020;8:300-317. [DOI: 10.1159/000511444] [Reference Citation Analysis]
331 赵 光. Prognostic Significance of the Bloodcell Parameters in Patients with Metastatic Gastric Cancer. ACM 2020;10:1312-1323. [DOI: 10.12677/acm.2020.107199] [Reference Citation Analysis]
332 Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J Clin Med 2019;9:E102. [PMID: 31906082 DOI: 10.3390/jcm9010102] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
333 Rotem R, Erenberg M, Rottenstreich M, Segal D, Yohay Z, Idan I, Yohay D, Weintraub AY. Early prediction of post cesarean section infection using simple hematological biomarkers: A case control study. Eur J Obstet Gynecol Reprod Biol 2020;245:84-8. [PMID: 31884150 DOI: 10.1016/j.ejogrb.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
334 Baseri B, Samra B, Tam E, Chiu E, Leaf A. An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Case Rep Oncol Med 2019;2019:1816472. [PMID: 31885970 DOI: 10.1155/2019/1816472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
335 Shi XY, Yi FS, Wang Z, Qiao X, Zhai K. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion. Thorac Cancer 2020;11:320-8. [PMID: 31837116 DOI: 10.1111/1759-7714.13262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
336 Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. Cancers (Basel) 2019;11:E1954. [PMID: 31817541 DOI: 10.3390/cancers11121954] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
337 Martini DJ, Liu Y, Shabto JM, Carthon BC, Hitron EE, Russler GA, Caulfield S, Kissick HT, Harris WB, Kucuk O, Master VA, Bilen MA. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist 2020;25:e484-91. [PMID: 32162798 DOI: 10.1634/theoncologist.2019-0578] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
338 Zhou C, Zhong X, Song Y, Shi J, Wu Z, Guo Z, Sun J, Wang Z. Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence. Front Oncol 2019;9:1321. [PMID: 31850212 DOI: 10.3389/fonc.2019.01321] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
339 Vilhonen H, Kurki S, Laitinen T, Hirsjärvi S. Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. Medicina (Kaunas) 2019;55:E743. [PMID: 31744064 DOI: 10.3390/medicina55110743] [Reference Citation Analysis]
340 Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B. Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients? Cancers (Basel) 2019;11:E1784. [PMID: 31766292 DOI: 10.3390/cancers11111784] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
341 Yang Y, Xu H, Yang G, Yang L, Li J, Wang Y. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. Asia Pac J Clin Oncol 2020;16:63-9. [PMID: 31721468 DOI: 10.1111/ajco.13284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
342 Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020;126:260-70. [PMID: 31691957 DOI: 10.1002/cncr.32468] [Cited by in Crossref: 107] [Cited by in F6Publishing: 120] [Article Influence: 26.8] [Reference Citation Analysis]
343 Cayrefourcq L, Alix-panabières C. CTCs as Liquid Biopsy: Where Are We Now? Molecular Medicine 2019. [DOI: 10.5772/intechopen.84366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
344 Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int 2019;39:2008-23. [PMID: 31433891 DOI: 10.1111/liv.14220] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
345 Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol 2020;38:3.e17-27. [PMID: 31676278 DOI: 10.1016/j.urolonc.2019.09.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
346 Xu H, He A, Liu A, Tong W, Cao D. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Int Immunopharmacol 2019;77:105957. [PMID: 31677498 DOI: 10.1016/j.intimp.2019.105957] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
347 Kumar C, Bagga J, Chiliveru S, Kohli S, Bharadwaj A, Jain M, Inamdar S, Sharan B. Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy. Future Sci OA 2019;5:FSO435. [PMID: 31827897 DOI: 10.2144/fsoa-2019-0086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Wang X, Cao L, Li S, Wang F, Huang D, Jiang R. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer. J Cancer 2019;10:6703-10. [PMID: 31777599 DOI: 10.7150/jca.34469] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
349 Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini C, Torniai M, Fiordoliva I, Newsom-Davis T. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Ann Transl Med 2019;7:572. [PMID: 31807553 DOI: 10.21037/atm.2019.09.18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
350 Moosazadeh M, Maleki I, Alizadeh-Navaei R, Kheradmand M, Hedayatizadeh-Omran A, Shamshirian A, Barzegar A. Normal values of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio among Iranian population: Results of Tabari cohort. Caspian J Intern Med 2019;10:320-5. [PMID: 31558995 DOI: 10.22088/cjim.10.3.320] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
351 Lecot P, Sarabi M, Pereira Abrantes M, Mussard J, Koenderman L, Caux C, Bendriss-Vermare N, Michallet MC. Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Front Immunol 2019;10:2155. [PMID: 31616408 DOI: 10.3389/fimmu.2019.02155] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 20.5] [Reference Citation Analysis]
352 Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. Int J Clin Oncol 2020;25:74-81. [PMID: 31531785 DOI: 10.1007/s10147-019-01539-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
353 Bath J, Smith JB, Kruse RL, Vogel TR. Association of neutrophil-to-lymphocyte ratio with outcomes after elective abdominal aortic aneurysm repair. J Vasc Nurs 2019;37:213-20. [PMID: 31727313 DOI: 10.1016/j.jvn.2019.06.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
354 Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol 2020;25:135-44. [DOI: 10.1007/s10147-019-01528-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
355 Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy 2018;10:681-94. [PMID: 29882691 DOI: 10.2217/imt-2017-0175] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
356 Ercetin E, Richtmann S, Delgado BM, Gomez-Mariano G, Wrenger S, Korenbaum E, Liu B, DeLuca D, Kühnel MP, Jonigk D, Yuskaeva K, Warth A, Muley T, Winter H, Meister M, Welte T, Janciauskiene S, Schneider MA. Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. Cancers (Basel) 2019;11:E1306. [PMID: 31487965 DOI: 10.3390/cancers11091306] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
357 Rassy E, Mezquita L, Remon J, Besse B. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors? Immunotherapy 2019;11:1149-60. [DOI: 10.2217/imt-2019-0071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
358 Ohba T, Takamori S, Toyozawa R, Nosaki K, Umeyama Y, Haratake N, Miura N, Yamaguchi M, Taguchi K, Seto T, Shimokawa M, Takenoyama M. Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. J Thorac Dis 2019;11:3757-68. [PMID: 31656648 DOI: 10.21037/jtd.2019.09.29] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
359 Wang L, Zhao D, Qin K, Rehman FU, Zhang X. Effect and biomarker of Nivolumab for non–small-cell lung cancer. Biomedicine & Pharmacotherapy 2019;117:109199. [DOI: 10.1016/j.biopha.2019.109199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
360 Li B, Wang S, Li C, Guo M, Xu Y, Sun X, Yu J, Wang L. The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients. J Cancer 2019;10:5082-9. [PMID: 31602260 DOI: 10.7150/jca.30478] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
361 Lee J, Lee SJ, Kim K, Kim ST, Jang KT, Lee J. Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. BMC Cancer 2019;19:805. [PMID: 31412814 DOI: 10.1186/s12885-019-6030-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
362 Shoji F, Takeoka H, Kozuma Y, Toyokawa G, Yamazaki K, Ichiki M, Takeo S. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 2019;136:45-51. [PMID: 31437663 DOI: 10.1016/j.lungcan.2019.08.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 49] [Article Influence: 10.3] [Reference Citation Analysis]
363 Kim T, Choi H, Oak CH, Jang TW, Jung MH, Kim J. Correlation between stage of small-cell lung cancer and inflammatory factors. Asian Cardiovasc Thorac Ann 2019;27:554-8. [PMID: 31379186 DOI: 10.1177/0218492319868407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
364 Fang Y, Yang Y, Chen M, He P, Cheng L, Chen J, Wu H. Elevated peripheral inflammatory markers are related with the recurrence and canceration of vocal fold leukoplakia. Eur Arch Otorhinolaryngol 2019;276:2857-64. [PMID: 31367834 DOI: 10.1007/s00405-019-05576-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
365 Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol 2019;15:2743-57. [PMID: 31339060 DOI: 10.2217/fon-2019-0055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
366 Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, Kimura S, Sueoka-Aragane N. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 2019;10:1798-804. [PMID: 31328416 DOI: 10.1111/1759-7714.13149] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
367 Anami S, Doi H, Nakamatsu K, Uehara T, Wada Y, Fukuda K, Inada M, Ishikawa K, Kanamori S, Nishimura Y. Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy. J Radiat Res 2019;60:257-63. [PMID: 30576550 DOI: 10.1093/jrr/rry107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
368 Kanaji N, Tadokoro A, Watanabe N, Inoue T, Kadowaki N, Ishii T. Association of specific metastatic organs with the prognosis and chemotherapeutic response in patients with advanced lung cancer. Respir Investig 2019;57:472-80. [PMID: 31327681 DOI: 10.1016/j.resinv.2019.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
369 Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, Vergnenègre C, Veillon R, Vergnenègre A. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. PLoS One 2019;14:e0219060. [PMID: 31314761 DOI: 10.1371/journal.pone.0219060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
370 Lin JX, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu R, Huang ZN, Lin JL, Zheng CH, Huang CM, Li P. Association of the age-adjusted Charlson Comorbidity Index and systemic inflammation with survival in gastric cancer patients after radical gastrectomy. Eur J Surg Oncol 2019;45:2465-72. [PMID: 31350072 DOI: 10.1016/j.ejso.2019.07.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
371 Xie X, Liu J, Yang H, Chen H, Zhou S, Lin H, Liao Z, Ding Y, Ling L, Wang X. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. Cancer Investigation 2019;37:265-74. [DOI: 10.1080/07357907.2019.1639057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
372 Haanen J. Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs. ESMO Open 2019;4:e000557. [PMID: 31423339 DOI: 10.1136/esmoopen-2019-000557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
373 Huemer F, Lang D, Westphal T, Gampenrieder SP, Hutarew G, Weiss L, Hackl H, Lamprecht B, Rinnerthaler G, Greil R. Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. J Clin Med 2019;8:E1014. [PMID: 31295966 DOI: 10.3390/jcm8071014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
374 Pasini L, Ulivi P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. J Clin Med 2019;8:E998. [PMID: 31323990 DOI: 10.3390/jcm8070998] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
375 Qi Y, Liao D, Fu X, Gao Q, Zhang Y. Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. Int Immunopharmacol 2019;74:105707. [PMID: 31272066 DOI: 10.1016/j.intimp.2019.105707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
376 Zhang Y, Chen B. Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis. Dis Markers 2019;2019:2513026. [PMID: 31354887 DOI: 10.1155/2019/2513026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
377 Huang Y, Ding H, Wu Q, Li Z, Li H, Li S, Xie C, Zhong Y. Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas. Cancer Manag Res 2019;11:6003-9. [PMID: 31303796 DOI: 10.2147/CMAR.S202546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
378 Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. J Pathol 2019;249:151-65. [PMID: 31102277 DOI: 10.1002/path.5306] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
379 Fu Y, Yang X, Liang H, Wu X. Serum hepatitis B viral (HBV) DNA is a predictive biomarker for survival in non-small cell lung cancer patients with chronic HBV infection. Cancer Manag Res 2019;11:5091-100. [PMID: 31213920 DOI: 10.2147/CMAR.S198714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
380 Chen H, Xue H, Liu W, Wu F, Wang Y, Gao H. [Meta-analysis of Platelet Lymphocyte Ratio as A Prognostic Factor for
Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:289-98. [PMID: 31109438 DOI: 10.3779/j.issn.1009-3419.2019.05.05] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
381 Takada K, Shimokawa M, Tanaka K, Kohashi K, Haro A, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Oda Y, Mori M. Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. PLoS One 2019;14:e0217991. [PMID: 31163080 DOI: 10.1371/journal.pone.0217991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
382 Wang Z, Zhan P, Lv Y, Shen K, Wei Y, Liu H, Song Y. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res 2019;8:214-26. [PMID: 31367535 DOI: 10.21037/tlcr.2019.06.10] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
383 Noé G, Bellesoeur A, Golmard L, Thomas-Schoemann A, Boudou-Rouquette P, Tiako Meyo M, Puszkiel A, Arrondeau J, Alexandre J, Goldwasser F, Blanchet B, Vidal M. Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Cancers (Basel) 2019;11:E762. [PMID: 31159331 DOI: 10.3390/cancers11060762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
384 Schoenfeld AJ, Ferrone ML, Schwab JH, Blucher JA, Barton LB, Harris MB, Kang JD. Prognosticating outcomes and survival for patients with lumbar spinal metastases: Results of a bayesian regression analysis. Clin Neurol Neurosurg 2019;181:98-103. [PMID: 31029015 DOI: 10.1016/j.clineuro.2019.04.009] [Reference Citation Analysis]
385 Wang X, Zhang B, Chen X, Mo H, Wu D, Lan B, Li Q, Xu B, Huang J. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. Thorac Cancer 2019;10:1395-401. [PMID: 31017739 DOI: 10.1111/1759-7714.13083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
386 Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist 2019;24:1128-36. [PMID: 31015312 DOI: 10.1634/theoncologist.2018-0563] [Cited by in Crossref: 80] [Cited by in F6Publishing: 92] [Article Influence: 20.0] [Reference Citation Analysis]
387 Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer. World J Oncol 2019;10:90-100. [PMID: 31068989 DOI: 10.14740/wjon1193] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
388 McFarland DC. New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. Gen Hosp Psychiatry 2019;60:148-55. [PMID: 31056371 DOI: 10.1016/j.genhosppsych.2019.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
389 Li S, Xu H, Wang W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, Ni Q, Yu X, Wu C, Liu L. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res 2019;11:3327-37. [PMID: 31114368 DOI: 10.2147/CMAR.S197911] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
390 Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calò V, Listì A, Mazzarisi S, Perez A, Gallina G, Rizzo S, Soto Parra H, Bazan V, Russo A. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. Ther Adv Med Oncol 2019;11:1758835919839928. [PMID: 31019571 DOI: 10.1177/1758835919839928] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
391 Teishima J, Inoue S, Hayashi T, Matsubara A. Current status of prognostic factors in patients with metastatic renal cell carcinoma. Int J Urol. 2019;26:608-617. [PMID: 30959579 DOI: 10.1111/iju.13956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
392 Kiriu T, Yamamoto M, Nagano T, Koyama K, Katsurada M, Tamura D, Nakata K, Tachihara M, Kobayashi K, Nishimura Y. Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. In Vivo 2019;33:213-20. [PMID: 30587626 DOI: 10.21873/invivo.11462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
393 Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N, Tanimura K, Harita S, Imabayashi T, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. J Clin Med 2019;8:E450. [PMID: 30987236 DOI: 10.3390/jcm8040450] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
394 Ichiki Y, Taira A, Chikaishi Y, Matsumiya H, Mori M, Kanayama M, Nabe Y, Shinohara S, Kuwata T, Takenaka M, Oka S, Hirai A, Imanishi N, Yoneda K, Kuroda K, Fujino Y, Tanaka F. Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. J Thorac Dis 2019;11:1117-23. [PMID: 31179053 DOI: 10.21037/jtd.2019.04.41] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
395 Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med 2019;17:74. [PMID: 30849967 DOI: 10.1186/s12967-019-1828-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
396 Zhang Z, Li Y, Yan X, Song Q, Wang G, Hu Y, Jiao S, Wang J. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Cancer Med 2019;8:1467-73. [PMID: 30848091 DOI: 10.1002/cam4.2024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 16.3] [Reference Citation Analysis]
397 Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 2019;4:e000457. [PMID: 30964126 DOI: 10.1136/esmoopen-2018-000457] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 24.3] [Reference Citation Analysis]
398 Bozkaya Y, Kurt B, Gürler F. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width. Int J Clin Oncol 2019;24:798-806. [PMID: 30783810 DOI: 10.1007/s10147-019-01417-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
399 Sebastian N, Wu T, Bazan J, Driscoll E, Willers H, Yegya-Raman N, Bond L, Dwivedi A, Mo X, Tan Y, Xu-Welliver M, Haglund K, Jabbour SK, Keane FK, Williams TM. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol 2019;134:151-7. [PMID: 31005209 DOI: 10.1016/j.radonc.2019.01.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
400 Mathur K, Kurbanova N, Qayyum R. Platelet-lymphocyte ratio (PLR) and all-cause mortality in general population: insights from national health and nutrition education survey. Platelets 2019;30:1036-41. [PMID: 30759051 DOI: 10.1080/09537104.2019.1571188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
401 Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, Ren S, Chen X, Zhou C. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer 2019;130:76-83. [PMID: 30885355 DOI: 10.1016/j.lungcan.2019.02.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
402 Guo D, Li M, Chen D, Jing W, Zhu H, Fu L, Kong L, Yue J, Yu J. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Future Oncology 2019;15:625-35. [DOI: 10.2217/fon-2018-0667] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
403 Huang Y, Wei S, Jiang N, Zhang L, Wang S, Cao X, Zhao Y, Wang P. The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis. BMC Cancer 2018;18:1235. [PMID: 30526532 DOI: 10.1186/s12885-018-5136-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
404 Diem S, Fässler M, Hasan Ali O, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018;10:5537-44. [PMID: 30519101 DOI: 10.2147/CMAR.S179767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
405 Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, Chen C, Chen Y. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int 2018;18:201. [PMID: 30534002 DOI: 10.1186/s12935-018-0698-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
406 Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer 2019;106:144-59. [PMID: 30528799 DOI: 10.1016/j.ejca.2018.11.002] [Cited by in Crossref: 117] [Cited by in F6Publishing: 126] [Article Influence: 23.4] [Reference Citation Analysis]
407 Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer 2018;6:129. [PMID: 30470260 DOI: 10.1186/s40425-018-0447-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 12.4] [Reference Citation Analysis]
408 Campedel L, Assoun S, Bécourt S, Nguyen O, Ledoux F, Doucet L, Espié M, Teixeira L, Maizel J, Vinsonneau C. Toxicités sévères des immunothérapies du cancer. Méd Intensive Réa 2018;27:522-36. [DOI: 10.3166/rea-2018-0070] [Reference Citation Analysis]
409 Chen S, Li X, Lv H, Wen X, Ding Q, Xue N, Su H, Chen H. Prognostic Dynamic Nomogram Integrated with Inflammation-Based Factors for Non-Small Cell Lung Cancer Patients with Chronic Hepatitis B Viral Infection. Int J Biol Sci 2018;14:1813-21. [PMID: 30443185 DOI: 10.7150/ijbs.27260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
410 Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy: Inflammatory Biomarkers in Immunotherapy. Cancer 2019;125:127-34. [DOI: 10.1002/cncr.31778] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 14.4] [Reference Citation Analysis]
411 Xu GW, Wu HR, Xiong R, Li CW, Liu CQ, Xu MQ, Xie MR. Value of the preoperative neutrophil-to-lymphocyte ratio as a prognostic factor for long-term survival in postoperative esophageal squamous cell carcinoma patients. Thorac Cancer 2018;9:1707-15. [PMID: 30311998 DOI: 10.1111/1759-7714.12885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
412 Tong M, Wang J, He W, Wang Y, Pan H, Li D, Zhang H. Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res 2018;10:4501-7. [PMID: 30349382 DOI: 10.2147/CMAR.S179680] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
413 Zhu Z, Xu L, Zhuang L, Ning Z, Zhang C, Yan X, Lin J, Shen Y, Wang P, Meng Z. Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma. Onco Targets Ther. 2018;11:6731-6740. [PMID: 30349306 DOI: 10.2147/ott.s173275] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
414 Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M, Yasui H. Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget 2018;9:34520-7. [PMID: 30349646 DOI: 10.18632/oncotarget.26145] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
415 Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol 2019;26:31-47. [PMID: 30253448 DOI: 10.1111/iju.13801] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
416 Wójcik E, Stasik Z, Rychlik U, Tarapacz J, Kanty Kulpa J, Sas-korczynska B. Prognostic value of Platelet-to-Lymphocyte Ratio (PLR) and IL-6 in patients with small cell lung cancer. diagn lab 2018;54:137-144. [DOI: 10.5604/01.3001.0013.7698] [Reference Citation Analysis]
417 Tan Q, Liu S, Liang C, Han X, Shi Y. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis. Thorac Cancer 2018;9:1220-30. [PMID: 30151899 DOI: 10.1111/1759-7714.12815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
418 Cao D, Xu H, Xu X, Guo T, Ge W. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncoimmunology 2018;7:e1507262. [PMID: 30377569 DOI: 10.1080/2162402X.2018.1507262] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
419 Sekine K, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Ohe Y. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer 2018;124:179-88. [PMID: 30268458 DOI: 10.1016/j.lungcan.2018.08.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
420 Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng BB, Ling CQ. Prognostic Role of Platelet-to-Lymphocyte Ratio in Hepatocellular Carcinoma with Different BCLC Stages: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018;2018:5670949. [PMID: 30158964 DOI: 10.1155/2018/5670949] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
421 Kim HJ, Jo MJ, Kim BR, Kim JL, Jeong YA, Na YJ, Park SH, Lee SY, Lee DH, Kim BH, Yoo YD, Oh SC. Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. Onco Targets Ther 2018;11:4233-46. [PMID: 30087567 DOI: 10.2147/OTT.S161587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
422 Cui X, Zhu S, Tao Z, Deng X, Wang Y, Gao Y, Liao Y, Ma W, Zhang Y, Ma X. Long-term outcomes and prognostic markers in gallbladder cancer. Medicine (Baltimore) 2018;97:e11396. [PMID: 29995783 DOI: 10.1097/MD.0000000000011396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
423 Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdona S, Verze P, La Rocca R, Borghesi M, Schiavina R, Brunocilla E, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Serretta V, Russo GI, Morgia G, Terracciano D, Musi G, de Cobelli O, Mirone V, Shariat SF. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer 2018;16:445-52. [PMID: 30077463 DOI: 10.1016/j.clgc.2018.07.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
424 Parikh K, Kumar A, Ahmed J, Anwar A, Puccio C, Chun H, Fanucchi M, Lim SH. Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. Cancer Immunol Immunother 2018;67:1365-70. [DOI: 10.1007/s00262-018-2192-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
425 Buder-Bakhaya K, Hassel JC. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. Front Immunol 2018;9:1474. [PMID: 30002656 DOI: 10.3389/fimmu.2018.01474] [Cited by in Crossref: 140] [Cited by in F6Publishing: 141] [Article Influence: 28.0] [Reference Citation Analysis]
426 Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol 2018;129:27-39. [PMID: 30097235 DOI: 10.1016/j.critrevonc.2018.06.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
427 Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol 2019;21:206-12. [PMID: 29948974 DOI: 10.1007/s12094-018-1908-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
428 Kataoka Y, Hirano K. Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors? Ann Transl Med 2018;6:222. [PMID: 30023385 DOI: 10.21037/atm.2018.04.17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
429 Naqash AR, Stroud CRG, Butt MU, Dy GK, Hegde A, Muzaffar M, Yang LV, Hafiz M, Cherry CR, Walker PR. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. Acta Oncol 2018;57:867-72. [PMID: 29241410 DOI: 10.1080/0284186X.2017.1415460] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
430 Passiglia F, Commendatore O, Vitali M, Conca R. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. Future Oncology 2018;14:41-60. [DOI: 10.2217/fon-2018-0098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
431 Hershko Klement A, Hadi E, Asali A, Shavit T, Wiser A, Haikin E, Barkan Y, Biron-Shental T, Zer A, Gadot Y. Neutrophils to lymphocytes ratio and platelets to lymphocytes ratio in pregnancy: A population study. PLoS One 2018;13:e0196706. [PMID: 29787560 DOI: 10.1371/journal.pone.0196706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
432 Guo D, Zhang J, Jing W, Liu J, Zhu H, Fu L, Li M, Kong L, Yue J, Yu J. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncol 2018;14:2643-50. [PMID: 29747545 DOI: 10.2217/fon-2018-0285] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
433 Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K. Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. Clin Lung Cancer 2019;20:208-214.e2. [PMID: 29803573 DOI: 10.1016/j.cllc.2018.04.021] [Cited by in Crossref: 47] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
434 Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Front Oncol 2018;8:107. [PMID: 29732316 DOI: 10.3389/fonc.2018.00107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
435 Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, Giordano A, Adamo V. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. J Cell Physiol 2018;233:6337-43. [PMID: 29672849 DOI: 10.1002/jcp.26609] [Cited by in Crossref: 59] [Cited by in F6Publishing: 71] [Article Influence: 11.8] [Reference Citation Analysis]
436 Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer 2018;9:1813-20. [PMID: 29805708 DOI: 10.7150/jca.24985] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
437 Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 2018;120:137-41. [PMID: 29748008 DOI: 10.1016/j.lungcan.2018.03.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
438 Anderson R, Rapoport BL. Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. Front Oncol 2018;8:80. [PMID: 29623257 DOI: 10.3389/fonc.2018.00080] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
439 Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Tamura D, Tachihara M, Kobayashi K, Nishimura Y. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One 2018;13:e0193018. [PMID: 29447258 DOI: 10.1371/journal.pone.0193018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
440 Ming L, Jiang Z, Ma J, Wang Q, Wu F, Ping J. Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and platelet indices in patients with acute deep vein thrombosis. Vasa 2018;47:143-7. [PMID: 29325504 DOI: 10.1024/0301-1526/a000683] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
441 Ponzetta A, Mantovani A, Jaillon S. Dissecting neutrophil complexity in cancer. Emerg Top Life Sci 2017;1:457-70. [PMID: 33525797 DOI: 10.1042/ETLS20170062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]